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Abstract 
EFFECT OF ACUTE DIETARY NITRATE SUPPLEMENTATION ON ARTERIAL 
BLOOD OXYGEN SATURATION AND TIME TRIAL PERFORMANCE DURING 
ACUTE HYPOXIC EXPOSURE IN MALE CYCLISTS AND TRIATHLETES. 
 
Jennifer Christine Arms 
B.S., Boston University 
M.S., Appalachian State University 
Chairperson: David Morris 
Previous investigations of high altitude exercise have demonstrated that hypoxia 
induced pulmonary vasoconstriction can be reduced and blood oxygen saturation levels and 
exercise performance can be partially restored through the use of pulmonary vasodilators 
such as phosphodiesterase (PDE-5) inhibitors.  Similarly, nitric oxide supplementation via 
exogenous nitric oxide and nitrite has been reported to cause pulmonary vasodilation; 
however, exogenous dietary nitrate, such as red beetroot juice, has only been tested and 
shown to cause vasodilation in the systemic circulation and has only been tested and shown 
to increase athletic aerobic exercise performance at normoxia, sea level.  PURPOSE: To 
determine the effect of short-term red beetroot juice supplementation on systemic blood 
pressure, exercising arterial blood oxygen saturation, and time trial performance during acute 
hypoxic exposure (FIO2 ~13%).  METHODS: Nine healthy competitive male cyclists and 
triathletes were randomly assigned in a crossover design to perform one time trial on a cycle 
ergometer while experiencing each of the three acute supplemental treatments: beetroot juice 
(BR), nitrate depleted beetroot juice (PL), and water (CO), 2.5 hours before each 
experimental time trial.  Systemic blood pressure was measured before the supplement was 
 v 
ingested and pre and post- warm-up after the supplement was ingested.  Oxygen saturation, 
completion time, and work rate were measured after approximately every 1/4 total kilojoules 
completed in addition to the total time trial completion time, work rate, cycling economy, 
and oxygen consumption for each experimental trial.  RESULTS:  No significant main 
effects due to treatment were observed in systolic blood pressure (BR vs PL, P=0.24; BR vs 
CO, P=0.35; PL vs CO, P=0.95), diastolic blood pressure (BR vs PL, P=0.99; BR vs CO, 
P=0.99; PL vs CO, P=0.98), and mean arterial pressure (BR vs PL, P=0.96; BR vs CO, 
P=0.62; PL vs CO, P>0.99).  No significant differences in time trial completion times (BR vs 
PL, P=0.33; BR vs CO, P=0.87; PL vs CO, P=0.50) (Mean ± SD: BR, 911.78 ± 163.07 sec; 
PL, 865.78 ± 131.02 sec; and CO, 888.44 ± 142.32) or work rates (BR vs PL, P=0.27; BR vs 
CO, P=0.91; PL vs CO, P=0.33) were observed when comparing the three treatments across 
total and segment results.  No significant differences were observed in oxygen saturation at 
each completion point during the time trial (BR vs PL, P=0.69; BR vs CO, P>0.99; PL vs 
CO, P=0.83).  Although no treatment effects were observed, time effects were observed in 
certain variables.  Finally, there were no significant treatment effects on oxygen consumption 
(BR vs PL, P=0.99; BR vs CO, P=0.99; PL vs CO, P=0.99) or mean cycling economy (Work 
Rate / Oxygen Consumption) (J*min-1/ml*min-1) during the time trial (BR vs PL, P=0.90; 
BR vs CO, P>0.99; PL vs CO, P=0.77).  CONCLUSION:  Acute beetroot juice 
supplementation did not affect systemic blood pressure, exercising arterial blood oxygen 
desaturation, and time trial cycling performance during acute hypoxic exposure.  Therefore, 
beetroot juice may not be a prospective aid to help improve hypoxic aerobic exercise 
performance. 
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Introduction 
As altitude increases, the inspired partial pressure of oxygen (PIO2) decreases (Hahn 
& Gore, 2001).  This decrease in PI02 reduces the available oxygen to the body (also known 
as hypoxia), and impairs the aerobic system, hindering optimal cycling performance, even in 
short events such as the 4000 m pursuit (Hahn & Gore, 2001). In addition to overall slower 
winning times for events (Martin, Levett, Grocott, & Montgomery, 2010), power output 
(work performed/time) has also been recorded to be lower at high altitude than those outputs 
at sea level for the same work intervals completed by cyclists (Hahn & Gore, 2001).  The 
level of impairment of the aerobic system is relative to the degree of altitude, intensity of 
exercise (Hahn & Gore, 2001), and training and acclimatization status of the athlete (Martin, 
Levett, Grocott, & Montgomery, 2010).  The physiological responses to aerobic exercise at 
hypoxia become exacerbated and the aerobic performance becomes more impaired as altitude 
increases (Bartsch & Saltin, 2008).  The degree of altitude can be categorized as low (500-
2000 m), moderate (2000-3000 m), high (3000-5500 m), and extreme (above 5500 m) 
(Bartsch & Saltin, 2008).  High altitude can be further defined as the “threshold...where there 
are noticeable physiological changes in response to the reduction in oxygen availability” 
(Martin et al., 2010, p.464), which can not be restored with acclimatization to a healthy 
response at sea level (Bartsch & Saltin, 2008); therefore, supplements that will reduce 
hypoxic pulmonary vasoconstriction may be of interest in improving performance and in 
making athletes more competitive at high altitude. 
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Background Physiology 
With exercise at sea level, the body increases ventilation (Hahn & Gore, 2001), 
cardiac output, and blood flow to supply oxygen and substrates to support the increased 
metabolic rate of working muscle (Sheel, MacNutt, & Querido, 2010).  High altitude 
complicates and limits this process of oxygen transport during exercise.  In addition to 
reduced oxygen availability, at altitude above 2500 m (moderate altitude), hypoxia causes a 
reflex mechanism of constricting pulmonary blood vessels in areas of lower oxygen content 
within minutes (Martin et al., 2010).  This increase in pulmonary vascular resistance 
decreases  the gas exchange interface between the lungs and blood (Blitzer, Loh, Roddy, 
Stamler, & Creager, 1996; Sheel et al., 2010), reduces pulmonary capillary blood transit 
times, and increases pulmonary arterial pressure (Martin et al., 2010; Sheel et al., 2010).  
These diffusion limitations lead to reduced arterial blood oxygen content.  In addition, the 
increase in pulmonary arterial pressure has been linked to pulmonary edema (fluid leaking 
out of the blood into the tissue) that further limits oxygen transfer from the lungs to the blood 
by increasing the area across which oxygen has to diffuse (Scherrer et al., 1996).  
Furthermore, the increased resistance exacerbates the load of which the right ventricle has to 
overcome to eject blood, resulting in a smaller amount of blood ejected (stroke volume) and 
less oxygen available to the body (Hsu et al., 2006).  The decreased oxygen availability is 
detrimental to aerobic exercise performance (Sawka, Convertino, Eichner, Schnieder, & 
Young, 2000).   
The body has several mechanisms to compensate for this decrease in oxygen 
availability and hypoxic pulmonary vasoconstriction.  The body reacts both acutely (within 
minutes) via hyperventilation (Martin et al., 2010), increased heart rate, and increased cardiac 
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output (Hahn & Gore, 2001), and chronically (within hours and days) via adaptations such as 
increased red blood cell volume / total blood volume percentage (Sawka et al., 2000), red 
blood cell production (Hahn & Gore, 2001), and alterations in skeletal muscle substrate 
utilization and metabolism (Hahn & Gore, 2001; Martin et al., 2010).  In addition, the 
systemic vasculature undergoes vasodilation in response to hypoxia, which increases blood 
flow better to support the oxygen demand of working tissue (Blitzer et al., 1996).  While 
these physiological changes do increase the oxygen available to the muscles, reducing the 
deficit in aerobic performance (Hahn & Gore, 2001), they are only able partially to 
compensate for the strain of high altitude or hypoxia (Bartsch & Saltin, 2008; Hahn & Gore, 
2001; Martin et al., 2010; Sawka et al., 2000; Sheel et al., 2010).  The end result is that high 
altitude performance is never able to reach that of sea-level or normoxic conditions (Martin 
et al., 2010).  
 
Proposed Mechanism of Improvement 
The decrease in arterial blood oxygen saturation observed at high altitude with 
increasing exercise is a result of the mismatch of lung ventilation to pulmonary blood flow 
(ventilation-perfusion mismatch) and a reduced gas exchange due to diffusion limitations and 
a reduced oxygen availability (Schoene, 2001).  Furthermore, Hahn & Gore (2001) and 
Blitzer et al. (1996) concluded that tissue oxygen extraction is very efficient and that 
systemic circulation reacts to hypoxia by increasing oxygen delivery to better support sub-
maximal aerobic performance at high altitude, respectively.  For those reasons, the on-
loading of oxygen at the lung and pulmonary blood oxygen delivery should be examined as a 
possible route to improve performance.   
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Specifically, pulmonary vasodilation can reduce hypoxia-induced arterial blood 
oxygen desaturation and increase oxygen delivery by increasing ventilation-perfusion 
matching and decreasing pulmonary arterial pressure and pulmonary vascular resistance, thus 
reducing the diffusion limitation (Scherrer et al., 1996; Zuckerbraun, George, & Gladwin, 
2011) and load on the heart (Hsu et al., 2006).  The use of pulmonary vasodilators has been 
shown to assist in reducing hypoxia-induced pulmonary vasoconstriction by decreasing 
pulmonary arterial pressure and chance of edema, re-routing more blood flow to better 
ventilated areas, increasing pulmonary-capillary blood transit time, and increasing the 
pulmonary capillary interface, allowing more efficient and effective oxygen exchange from 
the lung tissue to the blood (Scherrer et al., 1996).  A decrease in pulmonary vascular 
resistance has also been shown to reduce the increased pressure and load on the heart and 
result in a larger circulation of blood (and oxygen) to compensate for and support the 
physiological stress associated with high altitude (Gotshall, 2007).  In conclusion, pulmonary 
vasodilation enhances oxygen transfer between the lung and blood by minimizing the 
ventilation-perfusion mismatch and diffusion limitation while reducing the strain on the 
cardiovascular system from high altitude to increase the oxygen available to the body and 
thus better preserve exercise performance. 
 
The Effects of Nitric Oxide 
While the body does have a system that naturally responds to the stimulus of hypoxia 
with a mechanism of vasodilation in the systemic circulation, animal experiments show that 
this mechanism might not be as functional in the pulmonary circulation to counter or reduce 
the hypoxic vasoconstriction reflex (Blitzer et al., 1996).  Moreover, this compensatory 
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mechanism seems to be impaired in the pulmonary system in severe hypoxia (Blitzer et al., 
1996); therefore, additional assistance with vasodilation may be helpful and necessary in 
preserving performance in hypoxic conditions.  The body naturally converts L-arginine to 
nitric oxide via nitric oxide synthase (Zuckerbraun et al., 2011). Endothelial derived nitric 
oxide stimulates production of cyclic guanosine monophosphate, a second messenger 
responsible for signaling smooth muscle relaxation (Zuckerbraun et al., 2011), to induce 
vasodilation and reduce vascular resistance and pressure (Blitzer et al., 1996).  Furthermore, 
it has been supported that under acidic and hypoxic environments, such as those created 
during exercise and high altitude, respectively, this reaction can be enhanced (Rassaf et al., 
2007).  Rassaf et al. (2007) reported that the oxidation product of nitric oxide, plasma nitrite, 
in addition to age “predicts the maximal stress achieved and duration of exercise” (p.672).  
Not only is increased nitrite and therefore nitric oxide production related to hypoxia and 
vasodilation, but it also is related to increased exercise intensity and performance.   
 
Supplementation 
In addition to endogenous nitric oxide production, supplemental nitric oxide sources 
in the form of nebulized nitrite, infused sodium nitrite, and inhaled nitric oxide have been 
shown to increase pulmonary vasodilation in hypoxic environments resulting in decreased 
pulmonary vascular resistance and pulmonary arterial pressure in both humans and animals 
(Bailey et al., 2009; Ingram, Pinder, Bailey, Fraser, & James, 2010; Modin et al., 2001; 
Scherrer et al., 1996; Zuckerbraun et al., 2011; Zuckerbraun et al., 2010).  Inhaled nitric 
oxide has even been shown to help reduce pulmonary hypertension (high blood pressure) and 
re-route blood flow away from areas of high edema to areas of low edema (Scherrer et al., 
 6 
1996).  This increases oxygen saturation by reducing the ventilation perfusion mismatch and 
the difference in oxygen content between the lungs and blood (improving the diffusion 
limitation) in people with high altitude induced pulmonary edema (Scherrer et al., 1996).  In 
conclusion, exogenous sources of nitrite such as infused sodium nitrite and inhaled nebulized 
nitrite and nitric oxide have been reported to induce pulmonary vasodilation and reduce 
hypoxic pulmonary vasoconstriction while endogenous nitrite and nitric oxide levels have 
been linked to exercise performance.   
Another source of exogenous nitrate, dietary nitrate, is converted from nitrate to 
nitrite by bacteria-producing enzymes in saliva and the oral cavity, which then react with 
tissue specific enzymes to produce nitric oxide (Zuckerbraun et al., 2011).  Due to the 
invasiveness of pulmonary vascular resistance measurements, much of this research is based 
on animal models or the use of expensive indirect measures estimating pulmonary vascular 
resistance in humans (Gotshall, 2007; Ingram et al., 2010); therefore, most of the studies on 
dietary nitrate supplementation with humans only examined systemic vascular pressures and 
not pulmonary vascular pressures.  Studies have shown that dietary nitrates do have 
vasodilatory and blood pressure reduction properties when examining systemic vasculature in 
both humans (Webb et al., 2008) and primates (Kapil et al., 2010).  These experiments 
support that the nitrate ingredient reduces systemic blood pressure by initiating vasodilation 
via conversion of nitrate to nitrite to nitric oxide. 
Along with reducing systemic blood pressure (Vanhatalo et al., 2010), dietary nitrates 
have been linked to increases in exercise performance in humans (Bailey et al., 2009; 
Gotshall, 2007; Lansley et al., 2011; Vanhatalo et al., 2010).  Red beetroot, the dietary source 
used in the previous studies, is a vegetable with high nitrate content (Hord, Tang, & Bryan, 
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2009; Tamme et al., 2010).  Dietary nitrate supplementation via red beetroot juice has been 
reported to reduce oxygen cost during sub-maximal intensity exercise (Bailey et al., 2009; 
Vanhatalo et al., 2010), to improve high intensity exercise tolerance (Bailey et al., 2009; 
Vanhatalo et al., 2010), to improve time to exhaustion and peak power output during a ramp 
incremental to maximum test (Vanhatalo et al., 2010), and to improve cycling economy 
(power output/ work rate) and time trial performance (Lansley et al., 2011).  In summary, 
results from these experiments demonstrate that the nitrates in beetroot juice have a positive 
effect on aerobic performance. 
Overall, dietary nitrates via beetroot juice have been shown to initiate systemic 
vasodilation (Kapil et al., 2010; Webb et al., 2008) and to increase aerobic exercise 
performance at normoxia (sea level) (Bailey et al., 2009; Lansley et al., 2011; Vanhatalo et 
al., 2010); however, these studies that analyzed the effects of nitrate rich beetroot juice only 
examined blood pressure and vascular resistance in the systemic system, not the pulmonary 
system. They also only examined exercise performance at normoxia.  It is unknown if the 
nitrates in beetroot juice have effects on pulmonary vasculature and aerobic exercise 
performance at hypoxia.  Meanwhile, Gotshall (2007) concluded that phosphodiesterase 5 
(PDE-5) inhibitors, which work downstream to nitrates in the same vasodilatory pathway, 
reduce hypoxia-induced pulmonary vasoconstriction and improve exercise performance at 
high altitude or during hypoxia more than the body’s own compensatory mechanisms alone 
(Gotshall, 2007).  PDE-5 inhibitors were determined to increase arterial blood oxygen 
saturation and blood oxygen delivery (Ghofrani et al., 2004; Hsu et al., 2006; Richalet et al., 
2005) and lead to an increase in work capacity and thus aerobic exercise performance during 
hypoxic exposure (Ghofrani et al., 2004; Hsu et al., 2006; Richalet et al., 2005).  In addition, 
 8 
PDE-5 inhibitors have specific effects on the pulmonary system but do not reduce blood 
pressure in the systemic system at hypoxic (Gotshall, 2007).  This evidence demonstrates that 
the reduction of pulmonary vascular resistance is related to increases in oxygen availability 
to the body and increases in high altitude/ hypoxic performance.   
 
Statement of the Problem 
Previous studies have shown that pulmonary vasodilation increases arterial blood 
oxygen saturation and blood oxygen delivery (Ghofrani et al., 2004; Hsu et al., 2006; Ricart 
et al., 2005; Richalet et al., 2005) and leads to increases in aerobic exercise performance at 
high altitude and hypoxia (Ghofrani et al., 2004; Hsu et al., 2006; Richalet et al., 2005).  
While it is known that nitric oxide causes pulmonary vasodilation (Ingram et al., 2010; 
Scherrer et al., 1996; Zuckerbraun et al., 2011), sources of dietary nitrates, such as red 
beetroot juice, have only been examined in affecting systemic circulation (Kapil et al., 2010; 
Webb et al., 2008).  Furthermore, this systemic mechanism to improve aerobic performance 
has only been tested at normoxia (Bailey et al., 2009; Lansley et al., 2011; Vanhatalo et al., 
2010).  It is unknown if dietary nitrates can increase arterial blood oxygen saturation that is 
reduced due to hypoxia-induced pulmonary vasoconstriction and lead to an increase in high 
altitude/hypoxic acute exercise performance.  The purpose of this study was to determine the 
effect of short-term red beetroot juice supplementation on systemic blood pressure, 
exercising arterial blood oxygen saturation, and acute aerobic (approximately 200 kJ) time 
trial performance during acute hypoxic exposure (simulated high altitude (4300 m)) in male 
club level cyclists and triathletes. 
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Hypothesis 
Pulmonary vasodilation results in increased oxygen availability via increased blood 
oxygen content and increased blood oxygen delivery to help support aerobic performance 
(Gotshall, 2007), so an increase in blood oxygen saturation and blood volume ejected from 
the heart would suggest the occurrence of pulmonary vasodilation.  Because nitric oxide 
causes pulmonary vasodilation in hypoxia and red beetroot juice and pulmonary vasodilation 
have both been related to increases in aerobic performance, we hypothesized that acute 
supplementation of red beetroot juice, which is high in nitrate content, would lead to a 
decrease in systemic blood pressure, an increase in exercising arterial blood oxygen 
saturation, and a decrease in cycling time trial performance time during acute hypoxic 
exposure in male club level cyclists and triathletes. 
 
Significance of the Study 
Beetroot juice could potentially reduce the deficit in aerobic exercise performance 
seen at high altitude when compared to sea level. This is important because many sporting 
events are held at moderate to high altitude, where past aerobic performances were markedly 
affected (Martin et al., 2010).  Furthermore, evidence of this mechanism could be very 
significant and beneficial to multiple populations.  Not only could it help non-acclimatized 
athletes be more competitive at high altitude events, but it could also help military personnel 
and other workers perform duties better and more efficiently that would otherwise be limited 
in high altitude or hypoxic environments.  In addition, dietary nitrate induced pulmonary 
vasodilation may be a prospective aid for reducing pulmonary hypertension, hypoxia, and 
pulmonary edema, ultimately improving everyday performance in diseased populations 
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(Zuckerbraun et al., 2011).  While dietary nitrate, such as red beetroot juice,  is a natural 
vasodilator with few possible minor side effects at this acute dose (Bailey et al., 2009; 
Gilchrist, Winyard, & Benjamin, 2010) compared to other vasodilators such as PDE-5 
inhibitors (Gotshall, 2007), dietary nitrate supplementation is also more practical during 
performance and everyday activity since one can easily supplement without being restricted 
by inhalation and infusion mechanisms; therefore, it was beneficial to investigate the 
pulmonary vasodilatory potential of dietary nitrate in relation to hypoxic environments and 
exercise performance.
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Definition of Terms 
Acclimatization: a physiological process of adaption to an environmental stressor 
such as hypoxia 
Adenosine Triphosphate (ATP): a cellular energy transporter 
Afterload: the pressure or force in which the heart has to pump against to eject blood 
Alveoli: terminal gas exchanging tissue of the lung 
Aerobic capacity: the maximum amount of work that can be performed due the 
body’s rate of consuming and using oxygen to make energy 
Ambient barometric pressure: the total atmospheric pressure specific to altitude 
Artery (arterial): blood vessels leaving the heart carrying oxygenated blood such as 
the aortic artery leaving the heart; pulmonary arteries: blood vessels bringing deoxygenated 
blood from the peripheral circulation to become oxygenated at the lungs 
Capillary: terminal gas exchanging tissue of blood vessels 
Cardiac output: the amount of blood pumped per minute 
Chemiluminescence technique: a technique used for detection of various molecules 
and substance in a medium such as plasma nitrite 
Diffusion limitations: Impaired movement of molecules or substances (oxygen) from 
areas of high concentration to areas of low concentration. 
Diastolic blood pressure: the lowest pressure in the arteries; when the heart relaxes 
Echocardiography: non-invasive test that uses sound waves to create pictures of the 
heart; Doppler echocardiography: assesses cardiac tissue and blood velocity used to examine 
vascular and cardiac function such as pulmonary arterial blood pressure and cardiac output 
Edema: fluid that leaks out the blood vessels into the tissue 
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Ejection fraction: the fraction of blood ejected from the heart compared to the total 
blood volume in the heart; measure of stroke volume as a percentage of total blood volume in 
the heart 
Fraction of inspired oxygen (FIO2): the percentage/proportion of total inspired air in 
the lungs that is composed of oxygen 
Gas exchange threshold: the breakpoint during exercise in which carbon dioxide gas 
production increases disproportionally to the amount of oxygen consumed; a non-invasive 
estimate for anaerobic threshold: the point where the body has to rely more on energy 
systems that do not use oxygen to supply the energy need to support exercise (since the 
energy rate required exceeds the supply rate capable of the aerobic system which uses 
oxygen for energy production) 
Gas rebreathing technique: non-invasive procedure used to determine cardiac output 
via gas analysis after inspiration of two marker compounds 
High altitude: 3000 – 5500 m; the “threshold where there are [significant] noticeable 
physiological changes in response to the reduction in oxygen availability” which can not be 
restored with acclimatization to a healthy response at sea level (Bartsch & Saltin, 2008) 
Hypoxia: the reduction in oxygen available  
Kinetics: the movement of a molecule or substance 
Low altitude: 500 – 2000 m (Bartsch & Saltin, 2008) 
Moderate altitude: 2000 – 3000 m (Bartsch & Saltin, 2008) 
Normoxia: sea level conditions 
Partial pressure of inspired oxygen (PIO2): the pressure due to oxygen (amount of 
oxygen) in the inspired gas the reaches the lungs 
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Phosphodiesterase 5 inhibitors (PDE-5 inhibitors): oral pharmacological 
supplemental pulmonary vasodilators 
Pulmonary circulation: vasculature leaving the heart to become oxygenated at the 
lung and leaving the lung once it is oxygenated to be pumped to the periphery by the heart. 
Pulmonary Hypertension: high blood pressure in the pulmonary vasculature 
Pulmonary Vasoconstriction: the reduction of the diameter of pulmonary blood 
vessels 
Pulse oximeter: non-invasive instrument used to measure oxygen saturation and heart 
rate 
Sphygmomanometer: an instrument that uses an inflatable cuff to restrict blood flow 
in order to measure blood pressure 
Strain gauge plethysmography: technique used to determine blood flow through an 
artery to examine the dilatory properties of the artery in reaction to various stimuli 
Stroke volume: the amount of blood pumped per heart contraction 
Systemic circulation: peripheral vasculature (all vessels excluding the heart and 
pulmonary vasculature) 
Systolic blood pressure: the highest pressure in the arteries; when the heart contracts 
Vasodilation: increased diameter of blood vessels 
Ventilation-Perfusion matching: the matching of well ventilated alveoli (lung tissue) 
with well perfused pulmonary capillaries 
Work capacity: the maximum possible amount of work (force/distance) produced 
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Review of Literature 
Athletic performance is impaired at high altitude due to a decreased oxygen 
availability to the body to support aerobic exercise (Hahn & Gore, 2001; Martin et al., 2010; 
Scherrer et al., 1996; Schoene, 2001; Sheel et al., 2010).  Not only is the inspired partial 
pressure of oxygen (PIO2) reduced as altitude increases (Hahn & Gore, 2001), but the 
available oxygen is further limited by the hypoxia-induced reflex of pulmonary 
vasoconstriction within minutes of exposure to altitude above 2500 m (Martin et al., 2010).  
Pulmonary vasoconstriction reduces both the oxygen exchanged from the lung to the blood 
(reducing arterial blood oxygen saturation) and the blood oxygen delivered from the heart to 
the tissue; however, supplemental pulmonary vasodilation has been shown to attenuate 
hypoxic pulmonary vasoconstriction (Gotshall, 2007).  Supplemental pulmonary vasodilators 
also have shown potential of improving high altitude aerobic performance (Gotshall, 2007).  
While inhaled nitric oxide and infused and nebulized nitrite have been shown to cause 
pulmonary vasodilation in hypoxia (Ingram et al., 2010; Scherrer et al., 1996; Zuckerbraun et 
al., 2011), sources of dietary nitrate, such as red beetroot juice, have only been examined and 
shown to cause vasodilation in the systemic vasculature in normoxia (Kapil et al., 2010; 
Webb et al., 2008).  Dietary nitrate via red beetroot juice has also only been tested and shown 
to increase aerobic exercise performance in normoxia (Bailey et al., 2009; Lansley et al., 
2011; Vanhatalo et al., 2010). 
This review of literature examines previous research on: pulmonary vasodilation via 
phosphodiesterase 5 (PDE-5) inhibitors (Sildenafil) to reduce hypoxic pulmonary 
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vasoconstriction and increase high altitude/hypoxic performance, the vasodilatory effects of 
three sources of nitric oxide, and the effects of nitrates on performance at normoxia (sea 
level).  Along with examining this research, this knowledge was used to set up an experiment 
to fill in the gaps via connecting the three areas of interest: nitrate supplementation, 
pulmonary vasodilation, and high altitude/hypoxic aerobic exercise performance.  It is 
unknown if acute supplementation of dietary nitrates can decrease arterial blood oxygen 
desaturation that results from hypoxia-induced pulmonary vasoconstriction and can lead to 
an increase in hypoxic/high altitude acute aerobic performance.  The purpose of this study 
was to determine the effect of short-term dietary nitrate supplementation via red beetroot 
juice on systemic blood pressure, exercising arterial blood oxygen saturation, and acute 
aerobic (approximately 200 kJ) time trial performance during acute hypoxic exposure 
(simulated high altitude (4300 m)) in male club-level cyclists and triathletes. 
 
Pulmonary Vasodilators Improve Performance 
 Phosphodiesterase 5 (PDE-5) inhibitors are vasodilators that have previously been 
effective in treating pulmonary hypertension and are now being examined as a possible oral 
supplement to attenuate hypoxic pulmonary vasoconstriction during high altitude exposure 
(Gotshall, 2007).  PDE-5 inhibitors work downstream to nitrates in the same nitric oxide 
induced vasodilation pathway by increasing the activity of second messenger cyclic 
guanosine monophosphate (cGMP) ultimately leading to enhanced vasodilatory effects 
(Gotshall, 2007).  Four studies (Ghofrani et al., 2004; Hsu et al., 2006; Ricart et al., 2005; 
Richalet et al., 2005) have explored Sildenafil, an oral PDE-5 inhibitor, in relation to both 
pulmonary vasodilation and high altitude or hypoxic exercise performance.  Even though 
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each study used a slightly different procedure (hypoxic environment and exercise 
performance test), they found overall similar results just of different magnitudes which 
correlated with their specific parameters (degree of hypoxic environments, length of 
exposure, and type and intensity of exercise test).  In conclusion, Sildenafil significantly 
reduced pulmonary arterial pressure, increased oxygen saturation, increased cardiac output, 
and increased work rate (Ghofrani et al., 2004; Hsu et al., 2006; Ricart et al., 2005; Richalet 
et al., 2005). 
 
Pulmonary vasodilation.  Supplements are needed to attenuate the increased 
pulmonary vascular resistance characteristic to hypoxic environments in order to increase the 
oxygen available to working tissue (Gotshall, 2007).  Ricart et al. (2005) found that 
Sildenafil significantly decreased pulmonary arterial pressure during rest and exercise in 
hypoxia only, not in normoxia, suggesting that PDE-5 inhibitors work through relieving the 
pulmonary vasoconstriction only present in hypoxic situations.  Due to the invasiveness of 
heart catheterization to measure pulmonary arterial pressure directly to examine pulmonary 
vascular resistance, the three studies that examined the pulmonary vasculature, used 
echocardiography to measure pulmonary arterial pressure indirectly (Ghofrani et al., 2004; 
Ricart et al., 2005; Richalet et al., 2005); however, this technique is very hard to perform 
during exercise, and the results can be further skewed by the heart health of the subject and 
experience of the operator (Hsu et al., 2006).  Consequently, these results should only be 
examined in addition to other measures to draw a conclusion about pulmonary vascular 
resistance (Hsu et al., 2006).  Furthermore, there were slight differences in the protocol as to 
the time the pressure measurement was taken (right after exercise as in Ricart et al.’s study 
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(2005), during exercise as in Ghofrani et al.’s study (2004), or at rest post-exercise in 
Richalet et al.’s  study (2005)), which results in some variability in the data.  Along with 
measuring pulmonary arterial pressure, these experimenters also analyzed the presence of 
pulmonary vasoconstriction with other measures.  Hypoxic pulmonary vasoconstriction 
increases the pulmonary arterial pressure by increasing vascular resistance, decreases the gas 
exchanged at the lung by creating diffusion limitations, and decreases the blood ejected from 
the heart by increasing the load on the right ventricle (Hsu et al., 2006).  In addition to a 
decrease in pulmonary arterial pressure, increases in oxygen exchanged (blood oxygen 
saturation) and blood ejected (stroke volume SV) would suggest that vasodilation helped 
attenuate this constriction. 
 
Oxygen saturation.  While blood oxygen saturation did increase with the 
administration of Sildenafil compared to no supplementation at hypoxia in all the studies 
(Ghofrani et al., 2004; Hsu et al., 2006; Ricart et al., 2005; Richalet et al., 2005), the results 
varied due to the different exercise testing procedures, different hypoxic environment 
conditions, and individual subject variability.  While all four experiments studied aerobic 
exercise using a cycle ergometer, Ricart et al. (2005) and Hsu et al. (2006) both used constant 
work rate bouts of five minutes at 50% of a theoretical VO2max specific for the subject and 
thirty minutes at 55% of peak power output followed by a 6 km time trial, respectively.  They 
both recorded slightly lower improvements in oxygen saturation with the supplementation of 
Sildenafil than Richalet et al. (2005) and Ghofrani et al. (2004), who used incremental 
exercise to exhaustion bouts.  This is due to the intensity of exercise.  When exercise 
intensity increases, the metabolic rate of working tissue and therefore the physiological 
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stresses on the body increase to support the more intense exercise (Martin et al., 2010).  The 
body requires an increased amount of oxygen to support this larger magnitude of stress; 
however, when oxygen is limited such as at hypoxia, one’s physiological response to 
exercise is further impaired due to the increased deficit in oxygen required to meet the 
demands of the higher exercise intensity (Sheel et al., 2010). Because larger oxygen deficits 
are seen with higher intensity exercise, improvements in blood oxygen saturation levels 
would result in more substantial performance and physiological improvements than those 
less impaired at lower intensities.  The body is also impaired to a higher extent as altitude 
increases because less oxygen is available at higher altitudes (Bartsch & Saltin, 2008; Hahn 
& Gore, 2001).  This correlation is evident in the Hsu et al. (2006) and Ghofrani et al. (2004) 
studies.  When comparing both results of acute hypoxic exposure, Hsu et al. (2006) reported 
lower improvements with Sildenafil than Ghofrani et al. (2004), who tested at a higher 
degree of hypoxia.  Ricart et al. (2005) received a low value of oxygen saturation 
improvement with Sildenafil for their degree of hypoxia.  In addition to a shorter exercise 
bout and hypoxic exposure, their exercise protocol called for measurements taken post-
exercise and not at the end of exercise, thus leading to an underestimate of change in oxygen 
saturation (Ricart et al., 2005).  Finally, the length of exposure in the hypoxic environment 
led to variance in the results.  For these experiments, acute exposure can be defined as less 
than two hours while chronic exposure can be defined as six days.  Ghofrani  et al. (2004) 
used a double blind crossover study (to rule out most inter-individual variability) in which 
each athlete was exposed to both the placebo and Sildenafil treatments at both an acute 
hypoxic gas environment for two hours and a chronic six day hypoxic exposure at the actual 
corresponding altitude.  Sildenafil was reported to help oxygen saturation during the acute 
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hypoxic exposure but did not seem to help during the short term chronic high altitude 
exposure (Ghofrani et al., 2004).  Ghofrani et al. (2004) suggested that this difference could 
be due to short term exposure acclimatization effects that help improved ventilation-
perfusion matching and gas exchange during the six day exposure.  They concluded that 
Sildenafil just maintained the improved or slightly improved oxygenation in the chronic 
hypoxic environment (Ghofrani et al., 2004).  These acclimatization effects had not yet 
developed during the acute two-hour hypoxic exposure (Ghofrani et al., 2004). 
Several adaptations take place during short term acclimatization to help oxygen 
uptake from the lung.  Ventilation continues to increase as the peripheral chemoreceptors 
become more sensitive to hypoxia (Bartsch & Saltin, 2008).  This increased ventilation of the 
lung tissue enhances gas exchange which increases the oxygen content of the blood (Sawka 
et al., 2000).  Increased ventilation is a significant factor in enhancing blood oxygen 
saturation during the first two weeks of hypoxic exposure (Bartsch & Saltin, 2008).  
Therefore, Sildenafil would only help to maintain the improved or slightly improve oxygen 
saturation by reducing the constriction of the pulmonary tissue and increasing the area 
available for gas exchange.  As a result, it would seem less effective in increasing oxygen 
saturation in chronic hypoxic environments than acute hypoxic environments since 
adaptations have occurred in the chronic environments to offset partially the gas exchange 
impairment. 
Furthermore, chronic hypoxic exposure activates mechanisms that may reduce blood 
oxygen saturation measurements to allow for more efficient usage of available substrates or 
to increase the oxygen available to the muscle.  There are some adaptations in the skeletal 
muscle with more prolonged exposure to hypoxia such as altered substrate usage and 
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metabolism to decrease the reliance on and demand of oxygen (Hahn & Gore, 2001; Martin 
et al., 2010), which could skew the magnitude of the change in oxygen saturation.  In 
addition, within a few hours of high altitude exposure, 2,3 diphosphoglycerate concentration 
is elevated, which assists red blood cells with unloading oxygen from the blood to the 
muscles (Hahn & Gore, 2001).  This increased unloading at the muscle may cause the blood 
that is returning to the lungs to contain a lower oxygen saturation level so that once it 
becomes oxygenated, the level is not as high as it was originally since it had to overcome this 
deficit in saturation (Hahn & Gore, 2001).  This would skew the arterial blood oxygen 
saturation measurement making Sildenafil seem like it is not as effective in increasing 
oxygen saturation in the chronic hypoxic environment compared to acute hypoxic exposure.  
The muscle may be unloading some of that extra oxygen delivered due to Sildenafil 
supplementation and using it to increase exercise performance.  Hahn & Gore (2001) 
concluded that oxygen extraction at the muscle was highly efficient during acute altitude 
exposure, when referencing cyclists, which suggests on-loading oxygen and getting it to the 
muscle may be more of a significant factor to target for improvement during high altitude 
exercise.   
Additionally, chronically increased ventilation causes respiratory alkalosis (Bartsch & 
Saltin, 2008).  In return, the kidney excretes bicarbonate to help the acid-base balance 
(Bartsch & Saltin, 2008).  This consequently reduces the body’s acid-base buffering capacity 
(Bartsch & Saltin, 2008).  Furthermore, respiratory alkalosis manifests several days after 
exposure (Bartsch & Saltin, 2008).  Respiratory alkalosis is maintained for several days 
before reversing towards basal levels (Bartsch & Saltin, 2008).  The rate and magnitude of 
this reversal is negatively correlated to elevation (Bartsch & Saltin, 2008).  Meanwhile, the 
 21 
reduced buffering capacity leaves the body more vulnerable to the reduction in pH brought 
about by exercise ultimately resulting in a decrease in performance (Bartsch & Saltin, 2008).  
This reduction in pH has been shown to impair and slow the movement of oxygen (Sheel et 
al., 2010) from the lung to the blood and muscle.  This may reduce the effectiveness of 
Sildenafil in increasing blood oxygen saturation; however, this does not mean it is less 
effective in inducing vasodilation.  Pulmonary arterial pressure decreased in both acute and 
chronic environments while cardiac output (the amount of blood pumped per time) increased 
(Ghofrani et al., 2004), suggesting Sildenafil was effective in creating vasodilation in both 
environments.   
Since one way pulmonary vasodilation helps to increase the oxygen available is by 
increasing gas exchange (Ghofrani et al., 2004; Hsu et al., 2006), an increase in oxygen 
saturation would suggest the occurrence of pulmonary vasodilation.  The measurement of 
oxygen saturation to determine the presence of pulmonary vasodilation seems to be 
confounded by acclimatization factors in chronic hypoxic environments; therefore, this 
experiment used an acute hypoxic environment to determine if pulmonary vasodilation is 
attenuating pulmonary vasoconstriction by improving gas exchange and thus oxygen 
saturation.  Due to lack of access to expensive echocardiography instruments to measure 
indirectly pulmonary arterial pressure such as the Doppler system, and the invasiveness of 
the more accurate direct pulmonary vascular resistance measures such as a catheter, blood 
oxygen saturation was measured as evidence to suggest the presence of pulmonary 
vasodilation.  Because an increase in arterial blood oxygen saturation is one possible result of 
the reduction of pulmonary vasoconstriction, arterial blood oxygen saturation can give the 
investigator an idea of the degree of pulmonary vasculature tone.  Since a hypobaric chamber 
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or high altitude testing facility was not accessible or feasible for this experiment, an acute gas 
exposure was used.  The hypoxic environment mimicked that of 4300 m, similar to Richalet 
et al.’s study, with a corresponding 12.6-12.7% fraction of inspired oxygen (FIO2) gas 
compared to the normal 20.93% (West, 1996).  Furthermore, this is the altitude of Pike’s 
Peak in Colorado (West, 1996), which is a potential testing facility for further application and 
investigation. 
Even though a high altitude environment would be more realistic and applicable to 
athletes who have to ascend several days before a race and therefore undergo these short 
acclimatization effects, the acute exposure is still fairly applicable.  Sawka et al. (2000) 
determined that the contribution of hemoconcentration due to erythropoiesis to the increase 
in oxygen content at 4300 m is much less significant than the contribution by ventilatory 
acclimatization, which raises alveolar ventilation to increase gas exchange from the lung to 
the blood thus raising blood oxygen content.  This shows that improving mechanisms that 
interfere with gas exchange from the lung to the blood would be more significant in helping 
oxygen saturation at 4300 m than improving the blood’s oxygen carrying capacity.  This 
experimental test of pulmonary vasodilation in the acute setting is applicable to real life 
situations because it targets the same more substantial limiting factor (gas exchange) that 
ventilatory acclimatization does in chronic hypoxic exposure.  Vasodilation works to increase 
the interface of the alveolar membrane and pulmonary capillaries, reducing the pulmonary 
capillary transit time, and by matching ventilation with perfusion to accomplish the same 
goal of increased gas exchange.  Furthermore, the purpose was to study an acute bout of 
exercise (similar to that in all four studies) to simulate a race, not the chronic effects of 
training at high altitude.  During a shorter exposure, the situation is not further confounded 
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with more long term adaptations such as the increase in red blood cell mass that takes several 
weeks (Hahn & Gore, 2001).  This longer exposure would also not be applicable to athletes 
that ascend just a few days before a race and are not interested in training or able to train at 
high altitude.  This evidence suggests that pulmonary vasodilation, in an acute setting, would 
be validly measured by an increase in oxygen saturation (evidence of on-loading more 
oxygen) and applicable to a more realistic situation where an athlete only resides at high 
altitude for several days just to compete in a race. 
 
Blood oxygen delivery.  Pulmonary vasodilation also causes an increase in blood 
oxygen delivery by decreasing the load on the right ventricle, so it is able to pump out more 
blood (Hsu et al., 2006).  In addition, the reduction of pulmonary vasoconstriction would 
increase the venous return to the left ventricle so that stroke volume and cardiac output 
would increase and result in a larger circulation of blood to the working tissue (Hsu et al., 
2006).  Two studies measured stroke volume and concluded that there were significant 
increases in the volume of blood ejected with Sildenafil compared to the placebo (Ghofrani et 
al., 2004; Hsu et al., 2006).  This supports the idea that pulmonary vasodilation is effective in 
increasing blood oxygen delivery by decreasing the pressure (afterload: the pressure or force 
the heart has to contract against to eject blood) on the right ventricle and increasing the 
venous return at the left ventricle so more blood is pumped by the heart.  Ghofrani et al. 
(2004) recorded an increase in stroke volume in both acute hypoxic and chronic hypoxic 
environments.  This supports that vasodilation is effective in increasing the oxygen available 
to the body via increasing blood oxygen transport in both lengths of exposure.  Stroke 
volume would be a good factor to measure since it is a valid indicator of pulmonary 
 24 
vasodilation that is not confounded by the length of exposure; however, due to the lack of 
funding and access to the appropriate instruments, stroke volume was not measured in this 
experiment.  Oxygen saturation was the only available measure that could be used to suggest 
occurrence of pulmonary vasodilation in the current experiment.  This validates the 
requirement of the acute exposure set up even more.   
Overall, while stroke volume increased, there were some differences in 
cardiovascular variables between the studies.  Slightly different from Ghofrani et al. and Hsu 
et al., who recorded higher cardiac outputs with no significant change in heart rate, Richalet 
et al. (2005) concluded that cardiac output was similar with the use of Sildenafil to that 
without supplementation while heart rate actually decreased with the use of Sildenafil.  This 
suggests that stroke volume increased and was the determining factor for the maintenance of 
cardiac output (Richalet et al., 2005).  Moreover, Richalet et al. did use a larger dose and a 
chronic dosing pattern which could have resulted in a larger activation of this cGMP 
pathway.  At lower doses, Ricart et al. (2005), Ghofrani et al. (2004), and Hsu et al. (2006) 
found no significant differences between the heart rates with the different treatments in 
hypoxia.  Furthermore, Ricart et al. (2005) showed a tendency for the ejection fraction (a 
measure of stroke volume as a percentage of blood volume in the heart) to increase with 
Sildenafil.  This may have been significant if more subjects were used; they had to exclude 
three of the fourteen subjects.  In addition, the results may have been limited due to the time 
of measurement (after exercise was complete instead of measuring during the last portion of 
exercise as in the other experiments).  Overall, these measurements could have varied due to 
the use of different instruments.  Ricart et al. (2005) and Richalet et al. (2005) both used 
echocardiography, which is hard to use during exercise and requires a trained and 
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experienced operator to achieve accurate results.  In comparison, Ghofrani et al. (2004) used 
the gold standard gas-rebreathing technique, while Hsu et al. (2006) used Physioflow 
impedence cardiography with a device that is not yet validated for the situations of constant 
work rate exercise, simulated altitude, or Sildenafil supplementation.  Despite these 
differences, these experiments reported an increase in the amount of blood pumped displayed 
as an increase in stroke volume and cardiac output in addition to a decrease in pulmonary 
arterial pressure (Ghofrani et al., 2004; Ricart et al., 2005; Richalet et al., 2005).  This 
increase in blood oxygen delivery supports that these pressure results were indicative of 
vasodilation.  Overall, these studies supported that hypoxic pulmonary vasoconstriction is 
attenuated with pulmonary vasodilation displayed as an increase in oxygen uptake and blood 
oxygen delivery. 
 
Effects on performance.  Ghofrani et al. (2004), Richalet et al. (2005), and Hsu et al. 
(2006) concluded that Sildenafil ultimately improved exercise performance in hypoxia 
regardless of the type of test and whether work capacity was measured as peak watts, VO2 
max, or time trial performance.  As seen in the measured variables stated earlier, the 
variability in the improvement was correlated with the type of test, test intensity, degree of 
altitude, and length of exposure (Hahn & Gore, 2001).  When comparing acute hypoxic 
exposure to chronic exposure, Sildenafil seemed to improve performance during incremental 
exercise to exhaustion by a greater percentage of power output (peak watts) in the acute 
environment than in the chronic environment (Ghofrani et al., 2004).  This could be a result 
of several physiological changes seen in chronic exposure and not in acute exposure.  An 
increase in bicarbonate excretion decreases the body’s acid-base buffering capacity which 
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can severely limit intense performance (known to produce a highly acidic environment) for 
several days at or above altitudes of 2000 m (Bartsch & Saltin, 2008).  Furthermore, this 
increased ventilation may cause dehydration due to exacerbated evaporative loss from 
humidifying the dryer air characteristic of high altitude at a higher rate for a longer period of 
time (Sheel et al., 2010), also limiting performance.  In addition, alterations in skeletal 
muscle substrate usage and metabolism could also affect performance (Hahn & Gore, 2001; 
Martin et al., 2010).  Chronic exposure impaired the subjects to a greater extent because the 
chronic exposure resulted in more negative confounding factors that limit performance 
indirectly from the chronic reduction of oxygen availability.  During chronic exposure, the 
improvement in exercise performance with Sildenafil supplementation compared to the same 
exercise test with a placebo was less than that seen during acute exposure.  In addition, none 
of the performances were able to match those performances at normoxia (Gotshall, 2007), 
which suggests multiple factors of impairment. 
When examining intensity of the exercise bout over similar exposure lengths, 
intensity seemed to influence the degree of improvement of one’s exercise performance with 
supplementation. Ghofrani et al. (2004) used an incremental cycling to maximum test while 
Hsu et al. (2006) used a lower intensity constant work rate cycling test.  The results of the 
exercise tests showed that the higher intensity maximum test had a higher percentage of 
improvement with supplementation than the lower intensity constant work rate test.  This 
supports previous knowledge: as intensity increases, the aerobic system is impaired more 
(Hahn & Gore, 2001), and  performance is more impaired.  As a result, the physiological 
changes due to Sildenafil will have a larger impact on the performance.  (Ricart et al. (2005) 
did not measure performance; they only used a constant work rate exercise bout to measure 
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the physiological variables discussed previously.)  Lastly, Ghofrani et al. (2004) and Richalet 
et al. (2005) have concluded that Sildenafil did not have significant effects on the systemic 
physiological measures even though there were slight trends of inconsistencies.  The 
systemic circulation is overwhelmed by the hypoxia-induced vasodilation, so that the 
vasodilatory effect of Sildenfil on the systemic vasculature is not significant.  This shows that 
Sildenafil affects the pulmonary system (Ghofrani et al., 2004; Gotshall, 2007; Richalet et al., 
2005) without impairing other physiological adaptations and systems that support exercise 
(Richalet et al., 2005).  Overall, Sildenafil was able to reduce hypoxic pulmonary 
vasoconstriction by causing vasodilation of the pulmonary system.  This pulmonary 
vasodilation increased both gas exchange and blood oxygen delivery and ultimately 
improved hypoxic aerobic performance. 
 
Inter-subject variability.  Besides variability due to different experimental setups 
and different instruments used, when examining all the physiological measures, Richalet et 
al. (2005), Ricart et al. (2005), Ghofrani et al. (2004), and Hsu et al. (2006) discovered trends 
in the variability of responses between the subjects.  Variability in subject populations could 
have had some influence on the variance of the results in these four studies.  While Ricart et 
al. (2005), Richalet et al. (2005), and Hsu et al. (2006) all examined healthy males, Richalet 
et al. and Hsu et al. more specifically examined moderately trained males and trained male 
cyclists and triathletes, respectively.  Furthermore, Ghofrani et al. (2004) examined healthy 
males and healthy females who were experienced in traveling to altitudes of 3500 m or 6000 
m. Four main characteristics exist along a continuum and have different degrees of influence 
on one’s response to hypoxic exercise and supplementation.  First, variability could have 
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been present due to different levels of previous experience in both the length and the height 
of high altitude exposure between the subjects.  Ghofrani et al. (2004) examined subjects that 
had previous experience at two different levels of exposure; therefore, the two groups might 
have responded differently to the same level of high altitude exercise stress due to their 
acclimatization status (length of exposure and level of altitude) (Martin et al., 2010).  Bartsch 
and Saltin (2008) concluded that those with previous high altitude experience seemed to have 
a higher threshold before developing symptoms of high altitude illness such as headaches, 
gastrointestinal upset, fatigue, weakness, dizziness, difficulty sleeping, lack or appetite, and 
change in mental status than those with no previous experience (Scherrer et al., 1996).  This 
would result in variability and error within the same study and when comparing one study 
with those of experience, such as the Ghofrani et al. (2004) study, to those with no 
experience, such as the Richalet et al. (2005) study, if all the other variables were also the 
same.  Secondly, fitness level influences one’s response to hypoxic exercise.  In addition, 
Hsu et al. (2006) was able to determine that subjects who were more fit had a greater degree 
of impairment than those less fit and may have seen more benefit with supplementation.  Not 
only are training status and acclimatization status factors in determining one’s response to 
high altitude exercise, but genetics also plays a role (Martin et al., 2010).  Hsu et al. (2006) 
discussed variability in the degree of the response to the high altitude stress and also the 
response with Sildenafil.  They, in addition to other researchers, concluded that those who 
were more impaired by high altitude (prone) also seemed to show the most improvement 
with Sildenafil supplementation (responder) (Gotshall, 2007; Hsu et al., 2006).  Thirdly, 
inter-subject genetic variability seems to determine the degree of response to the type of 
supplement (responder vs. non-responder) and the degree of whether they are prone or 
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resistant to hypoxic vasoconstriction expressed along a continuum of symptoms.  Finally, sex 
may have some influence on one’s response to the type of supplementation, but Ghofrani et 
al. did not evaluate if there were differences in responses between males and females, which 
could have also led to some of the variability. 
To control for adaptations and this variability, this experiment only used male athletes 
of sufficient training status.  Both previous and current training experience was considered 
via examining training reports and fitness testing.  The level of previous altitude exposure 
was also delimited in the participant inclusion criteria to control for physiological 
adaptations.  Overall, even though there was variability, these studies provided evidence to 
support that pulmonary vasodilation reduces hypoxic vasoconstriction and improves hypoxic 
performance. 
 
Three Sources of Nitric Oxide Cause Vasodilation 
Endogenous.  The body does have a system that naturally responds to the stimulus of 
hypoxia with a mechanism of vasodilation in the systemic circulation (Blitzer et al., 1996).  
Nitric oxide production is regulated by endothelial cells which are responsible for controlling 
vascular tone (Blitzer et al., 1996).  Low oxygen availability stimulates endothelial cell 
enzymes to induce systemic vasodilation as a protective mechanism of increasing blood 
supply and therefore oxygen to meet the metabolic demands of systemic organs and working 
tissue (Blitzer et al., 1996).  Previous research has shown that the body naturally converts L-
arginine into nitric oxide which activates a cGMP linked chain reaction to induce 
vasodilation (Zuckerbraun et al., 2011).  This is the same pathway that the PDE-5 inhibitors 
manipulate to cause pulmonary vasodilation (Zuckerbraun et al., 2011).  In contrast, the 
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pulmonary circulation in humans undergoes a hypoxic reflex of pulmonary vasoconstriction 
(Bailey et al., 2009).  Low oxygen availability elicits a protective response of constricting 
pulmonary blood vessels so that profusion to poorly oxygenated areas is minimized to help 
improve oxygen transfer through matching ventilation of the lung to perfusion of the 
pulmonary capillaries (Blitzer et al., 1996).  Blitzer et al. (1996) examined the role of 
endogenous nitric oxide production and the degree of vascular response to an acute hypoxic 
stimulus in relation to both the systemic and pulmonary systems via measurements of 
systemic and pulmonary blood pressures in healthy men and women.  First, Blizter et al. 
(1996) showed that the nitric oxide synthase enzyme was responsible for the release of nitric 
oxide and thus regulating vascular tone since both pulmonary and systemic vascular 
pressures increased at normoxia with infusion of a nitric oxide synthase inhibitor (L-
NMMA).  Then, during acute exposure to hypoxic gas, systemic vascular resistance 
decreased while pulmonary vascular resistance increased (Blitzer et al., 1996).  Finally, when 
hypoxic exposure was maintained while L-NMMA was infused, systemic vascular resistance 
increased, and pulmonary vascular resistance increased even more compared to the hypoxia 
alone condition (Blitzer et al., 1996).  This shows that the same mechanism is responsible for 
vasodilation in both systemic and pulmonary circulations; however, it seems to be impaired 
in the pulmonary system during hypoxia.  As a result, supplementation has been an idea of 
interest to assist nitric oxide levels with vasodilation in the pulmonary system. 
 
Exogenous: nitrite or nitric oxide.  Supplementation via nitrite and nitric oxide has 
been examined in relation to the pulmonary system.  Nitrite has previously been shown to be 
reduced to nitric oxide ultimately to initiate vasodilation (Zuckerbraun et al., 2011).  
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Zuckerbraun et al. (2010) determined that nebulized nitrite was effectively able to reduce 
hypoxia-induced pulmonary hypertension in sedated rats and mice without affecting systemic 
arterial pressure.  With the use of inhibitors in both in vivo sedated animals and in vitro cell 
cultures, nitrite was determined to induce vasodilation via producing nitric oxide which 
increases cGMP activity (Zuckerbraun et al., 2010).  Furthermore, Zuckerbraun et al. found 
that this mechanism was dependent on tissue specific nitric oxide stimulating enzymes which 
are found in the pulmonary vasculature (Zuckerbraun et al., 2010).  Along with the level of 
tissue-specific enzyme activity, the level of activation of this mechanism has also previously 
been shown to be dependent on pH and oxygen concentration of the environment 
(Zuckerbraun et al., 2010).  When examining in vitro rat aortas, it was concluded that nitric 
oxide was generated from physiological level doses of nitrite (via sodium nitrite) to induce 
vasodilation in a pH dependent fashion (Modin et al., 2001).  The degree of vasodilatory 
activity was correlated with nitric oxide and nitrite concentrations (Modin et al., 2001).  
Vasodilation was increased in more acidic environments paralleling those seen in tissues 
during “hypoxia and increased metabolic activity” (Modin et al., 2001, p.15).  This suggests 
that the application of nitric oxide could improve pulmonary blood flow in hypoxic 
environments.   
While much of the research in examining the pulmonary vasodilatory effects of 
exogenous sources of nitric oxide have been examined in animals due to the invasiveness of 
pulmonary vascular measures, relatively little research in this area has been done using 
human subjects.  Those that did examine human subjects did so via estimates with indirect 
measures of pulmonary arterial pressure.  Ingram et al. (2010) analyzed the pulmonary 
circulation in response to infusion of low doses of sodium nitrite (to result in a plasma nitrite 
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level not more than double that of physiological levels) in healthy male humans at rest by 
estimating pulmonary vascular resistance with pulmonary arterial pressure measured via 
transthoracic echocardiography.  In addition, they examined systemic vascular resistance 
differences measured via strain gauge plethysmography of the forearm (Ingram et al., 2010). 
They concluded that both systems showed evidence of vasodilation after nitrite infusion in a 
12% oxygen hypoxic environment (Ingram et al., 2010) (similar to the environment used in 
this study).  The pulmonary system in that study showed prolonged effects of vasodilation 
after plasma nitrite levels returned to baseline while these effects ceased in the systemic 
system (systemic effects were correlated with plasma nitrite levels) (Ingram et al., 2010).  
Even though echocardiography is an indirect measure and can be affected by variables such 
as regurgitation, Ingram et al. (2010) concluded that these results were reliable since they 
were consistent with the results that used pulmonary acceleration time and isovolumic 
relaxation time to help assess pulmonary arterial pressure.  They suggested that pulmonary 
tissue may have a lower threshold or higher degree of sensitivity to exogenous sources of 
nitric oxide since it constricts in response to hypoxic environments while the systemic 
vasculature already dilates in response to hypoxic environments (Ingram et al., 2010).  This 
supports that exogenous nitrite can cause pulmonary vasodilation in healthy males at rest. 
Likewise, the effect of inhalation of nitric oxide has been examined in relation to 
pulmonary vasoconstriction resulting from acute hypoxic exposure (10% FIO2) and chronic 
hypoxic exposure (4559 m of altitude) in men and women who had a history of being prone 
to high altitude pulmonary edema and hypertension with those whom were resistant as 
determined from previous high altitude exposure (Scherrer et al., 1996).  Similar to the PDE-
5 inhibitor studies, nitric oxide reduced pulmonary arterial pressure, measured indirectly via 
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echocardiography, in both groups but more substantially in those prone to edema and 
hypertension (Scherrer et al., 1996).  This could be due to the responders (prone) and non-
responders (resistant) situation described earlier; those impaired the most are more likely to 
have larger benefits (improvements) with supplementation.  When examining the oxygen 
saturation of those under chronic hypoxic exposure after a several day sojourn, nitric oxide 
inhalation improved oxygen saturation in the prone subjects that did experience symptoms of 
edema (Scherrer et al., 1996).  Nitric oxide inhalation did not impair subjects that were prone 
but did not have current symptoms of edema based on radiography (Scherrer et al., 1996).  
Finally, application of nitric oxide reduced oxygen saturation in those resistant to edema 
(Scherrer et al., 1996).  This suggests that the nitric oxide helped the ventilation-perfusion 
matching in the first two groups of subjects while the resistant subjects did not have 
significant mismatches (Scherrer et al., 1996).  The third group of subjects were impaired 
because the added nitric oxide had to displace some of the partial pressure of oxygen (-4%) 
in the inhaled gas resulting in a lower oxygen content in the treatment gas (Scherrer et al., 
1996).  This is supported by the experiment in acute exposure (minutes) where both prone 
and resistant groups did not see improvement in their blood oxygen saturation (Scherrer et 
al., 1996).  The additional reduction in oxygen affected them similarly since they had not had 
time to adapt and improve ventilation-perfusion matching (chronic resistant) or develop 
edema that would further prevent ventilation–perfusion matching and gas exchange (chronic 
prone).  Furthermore, radiography was used to examine lung-perfusion in the subjects during 
the chronic altitude exposure (Scherrer et al., 1996).  Scherrer et al. (1996) was able to 
conclude that inhalation of nitric oxide effectively redistributed blood flow away from 
regions of poor ventilation and high edema to those regions of better ventilation and low 
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edema, improving gas exchange and oxygen saturation in those with pulmonary edema.  This 
suggested that nitric oxide reduces the effects of pulmonary vasoconstriction via decreasing 
pulmonary arterial pressure and rerouting blood flow to better ventilated areas to improve gas 
exchange in men and women at rest during hypoxic exposure.  A major disadvantage of these 
types of supplementation is that the mechanisms of inhalation and infusion are not practical 
in a field environment; therefore, supplementation via dietary nitrate ingestion may be a more 
applicable method. 
 
Exogenous: dietary nitrate.  Supplementation via dietary nitrate ingestion has been 
examined to determine its vasodilatory potential.  Dietary nitrate is converted into nitrite by 
bacteria produced enzymes in saliva and the oral cavity (Zuckerbraun et al., 2011).  Nitrite 
then reacts with tissue specific enzymes to produce nitric oxide (Zuckerbraun et al., 2011).  
Due to the invasiveness of pulmonary vascular resistance measures, much of the research is 
based on animal models or with the use of indirect measures to estimate pulmonary vascular 
resistance in humans; therefore, most of the studies on dietary nitrate supplementation with 
humans only examine the vasodilatory effects on systemic vasculature and not pulmonary 
vasculature.  Studies have shown that dietary nitrates do have vasodilatory and blood 
pressure reduction properties when examining systemic vasculature in both humans (Webb et 
al., 2008) and animals (Kapil et al., 2010). 
Kapil et al. (2010) compared blood pressure reduction and flow medicated dilation of 
the brachial artery in response to potassium nitrate, potassium chloride, and beetroot juice in 
healthy men and women during rest at normoxia.  They found that potassium nitrate of three 
different doses (248 mg, 744 mg, and 1488 mg of nitrate) significantly decreased systemic 
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blood pressure compared to potassium chloride and that the blood pressure effects followed a 
nitrate ingested dose dependent relationship with plasma nitrite and plasma cGMP 
concentrations measured using ozone chemiluminescence (Kapil et al., 2010).  This supports 
nitrate as an initiator of these changes via activation of the same second messenger (cGMP) 
as PDE-5 inhibitors that have been shown to cause pulmonary vasodilation. Likewise, 250 
mL of (5.5 mMol nitrate) beetroot juice also caused a significant decrease in systemic blood 
pressure that paralleled plasma nitrite and cGMP concentrations compared to 250 mL of 
water (Kapil et al., 2010).  These results showed that a nitrate containing juice has blood 
pressure lowering effects.  
Kapil et al. utilized infrared irritation to mediate vasodilation in the brachial artery.  
When examining flow mediated dilation of the brachial artery after an IR irritation, both 
beetroot juice and potassium nitrate significantly increased the diameter of the artery from 
before the IR stress (Kapil et al., 2010).  This supported that nitrates have vasodilatory effects 
in response to stress independent of the type of source (natural or pharmacological).  These 
statistically significant blood pressure reductions and systemic vasodilation results were also 
supported by a similar study with a larger nitrate dose of 500 mL (45.0 ± 2.6 mMol/L nitrate 
(22.5 mMol of nitrate)) of beetroot juice (Webb et al., 2008).  Furthermore, both studies 
reported that these changes were correlated with the peak plasma nitrite concentration at 2.5-
3 hours after nitrate ingestion (Kapil et al., 2010; Webb et al., 2008).   
Additionally, Kapil et al. (2010) found a sex specific response to nitrate 
supplementation by revealing sex specific differences in blood pressure reduction and plasma 
nitrite concentration after body weight was normalized in post hoc analysis.  They suggested 
that these differences were due to sex differences in nitrate processing: premenopausal 
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females had a higher plasma nitrite concentration after ingestion while they experienced a 
smaller reduction in blood pressure (Kapil et al., 2010).  This has been supported previously 
when examining nitric oxide synthase expression and activity comparing age-matched 
females and males (Kapil et al., 2010).  Increased basal sensitivity could be the reason why 
females have lower resting blood pressures than males without supplementation, which could 
become saturated with the addition of nitrate via supplementation and result in less of a 
reduction in blood pressure (Kapil et al., 2010).  Kapil et al. (2010) did not control for the 
influence of hormone variation during the menstrual cycle.  Since sex and hormones may 
further confound results, this experiment controlled for these influences by only examining 
male subjects.  Overall, these experiments related the dietary nitrate-induced reduction of 
systemic blood pressure to systemic vasodilation. 
 
Beetroot juice.  Red beetroot juice is a commonly used source for dietary nitrate 
supplementation.  Red beetroot is a vegetable with a very high nitrate content (classified as 
greater than 250 mg/100 g fresh weight) compared to other natural sources of nitrate (Hord et 
al., 2009).  In addition, it has been shown that nitrate rich vegetables, such as red beetroot, 
have approximately a 100% bioavailability of nitrate absorption from oral supplementation 
whether cooked or consumed raw in healthy subjects aged 18-35 years old (van Velzen, Sips, 
Schothorst, Lambers, & Meulenbelt, 2008).  Beetroot is commonly administered as juice, and 
the nitrate content of juice has been shown to be well preserved by refrigeration for twenty-
four hours after opening (Tamme et al., 2010).  Even though beetroot juice may have a 
slower activation time, it has a more practical oral administration compared to inhalation or 
infusion of nitric oxide or nitrite, respectively (Zuckerbraun et al., 2011).  Additionally, this 
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natural source of nitrate appears to have fewer side effects (red urine and stools) (Bailey et 
al., 2009; Gilchrist et al., 2010; Vanhatalo et al., 2010; Webb et al., 2008) when compared to 
other supplements such as PDE-5 inhibitors (headaches, dizziness, flushing, dyspepsia) 
(Gotshall, 2007; Hsu et al., 2006) at this acute dose.  For these reasons, beetroot juice is a 
commonly used source of exogenous nitrate supplementation in humans and was used as the 
nitrate source in this study. 
Overall, sources of exogenous nitrite oxide have been shown to cause pulmonary 
vasodilation; however, dietary nitrates have only been examined to cause systemic 
vasodilation in humans due to the invasiveness of direct measures and cost of indirect 
measures.  It is unknown if dietary nitrates, such as red beetroot juice, cause vasodilation in 
the pulmonary system.  This study was designed to monitor indirect indicators of pulmonary 
vasculature tone during beetroot juice supplementation under hypoxic conditions. 
 
Nitrate Effects on Performance 
 Endogenous nitric oxide has been shown to cause vasodilation to help improve blood 
flow and delivery in systemic vasculature to support the oxygen demands of working tissue 
(Blitzer et al., 1996).  Furthermore, under acidic and hypoxic environments, such as those 
created during exercise and high altitude, respectively, tissue specific enzyme production of 
nitric oxide can be enhanced along with the activity of enzymes that convert nitrite to 
produce nitric oxide (Rassaf et al., 2007).  While nitrite is converted to nitric oxide under 
hypoxic and acidic conditions, nitric oxide in the plasma is oxidized back to nitrite in normal 
resting conditions (Rassaf et al., 2007).  Rassaf et al. (2007) concluded that plasma nitrite is 
an oxidation product of nitric oxide production and represents the capacity of the body’s 
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ability to produce nitric oxide.  They examined plasma nitrite levels and flow-mediated 
dilation of the brachial artery in healthy males and females during a stepwise increase to 
maximum exercise test (Rassaf et al., 2007).  Rassaf et al. (2007) determined that exercise 
intensity was positively correlated to the post exercise plasma nitrite levels which paralleled 
vasodilation (level of mediated blood flow).  Furthermore, these post exercise plasma nitrite 
levels were positively correlated with the maximum exercise power achieved but were 
negatively correlated with age (Rassaf et al., 2007).  Administration of a nitric oxide synthase 
inhibitor after exercise inhibited plasma nitrite production, supporting that nitric oxide was 
produced by this mechanism in response to exercise (Rassaf et al., 2007).  Rassaf et al. were 
able to conclude that post exercise plasma nitrite levels: “the capacity of the vasculature to 
produce nitric oxide…together with age independently predicts the maximal stress achieved 
and duration of exercise.” (Rassaf et al., 2007, p.672)  These results linked exercise 
performance with the ability to produce nitric oxide.  Because age is a confounding factor of 
performance and nitric oxide production, this study only recruited subjects from a specific 
age range: 18-30 years old, due to access and the applicability of the competitive opportunity 
associated with this age.  In conclusion, increased nitrite and therefore nitric oxide 
production is related to increased exercise intensity and performance. 
 
Beetroot juice effects on performance.  The nitrates in red beetroot juice have been 
shown to increase aerobic performance at normoxia (Bailey et al., 2009; Lansley et al., 2011; 
Vanhatalo et al., 2010).  Similar to the dietary nitrate vasodilatory and blood pressure 
reduction studies, these beetroot juice studies have also only examined the physiological 
effects due to nitrate supplementation in the systemic circulation suggesting only systemic 
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methods of exercise improvement via beetroot juice.  Vanhatalo et al. (2010) utilized a 
double blind crossover study to compare acute (one dose 2.5 hours before test) and chronic  
(5 and 15 days) daily supplementation of 0.5 L of beetroot juice (5.2 mMol of Nitrate) to 0.5 
L of cordial juice placebo supplement in both healthy males and females.  In this 
investigation, cyclists performed two five minute moderate intensity (90% GET-gas 
exchange threshold ~ anaerobic threshold) submaxmial constant work rate exercise tests and 
a ramp incremental to exhaustion exercise test with each test separated by ten minutes 
(Vanhatalo et al., 2010).  Vanhatalo et al., reported a lower oxygen cost in the submaximal 
test, 2.5 hours after the first supplementation, that was maintained throughout the fifteen days 
(Vanhatalo et al., 2010).  Vanhatalo et al. (2010) reported that there were no significant 
changes in heart rate during exercise, which Kapil et al. (2010) reported at rest, suggesting 
that nitrates do not affect the contraction rate of the heart when affecting cardiac output and 
blood delivered.  When examining the incremental step to exhaustion test, the work rate 
associated with GET and peak power output did not significantly increase from the placebo 
and baseline until the test administered after fifteen days of supplementation (Vanhatalo et 
al., 2010).  In a similar study, Bailey et al. (2009) utilized a double blind crossover study to 
examine the last three days of (a six day) chronic supplementation of beetroot juice (5.5 
mMol of nitrate/day) or blackcurrant cordial juice in recreationally active men.  In this 
investigation, cyclists performed different tests across the last three days of supplementation.  
They performed two six minute moderate intensity (80% GET) submaximal constant work 
rate cycling tests on day 4.  During the last two days, they performed one six minute 
moderate constant work rate test and one severe intensity (70% difference between 80% GET 
and VO2 peak) constant work rate test either 6 minutes long on day 5 or until exhaustion on 
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day 6 with each test separated by twenty-five minutes (Bailey et al., 2009).  Bailey et al. 
(2009) observed similar results to Vanhatalo et al. (2010) finding a reduction in oxygen cost 
during the submaximal cycling test.  Furthermore, both Vanhatalo et al. and Bailey et al. 
reported a significantly elevated plasma nitrite level that was constant throughout 
supplementation and a reduced systemic blood pressure (Bailey et al., 2009; Vanhatalo et al., 
2010), showing no evidence of reduced sensitivity to chronic supplementation of nitrates 
(Vanhatalo et al., 2010).  Additionally, Bailey et al. (2009) discovered significantly increased 
blood flow and reduced muscle fractional oxygen extraction (supply : utilization) with 
beetroot supplementation during the moderate intensity test suggesting that muscle energy 
production became more efficient since oxygen consumption decreased during the moderate 
constant work rate bout.  The results of Bailey et al. (2009) also showed that time to 
exhaustion (exercise tolerance) was increased in the severe intensity constant work rate test 
with chronic supplementation of beetroot juice compared to placebo; however, this was done 
with a change in oxygen kinetics (the oxygen uptake slow component was reduced) without 
an alteration in fractional oxygen extraction.  The continued increase in oxygen consumption 
seen with heavy to severe intensity constant work rate exercise (Bailey et al., 2009) was 
reduced so that it took longer to reach maximum oxygen consumption, extending 
performance.  Overall, these results showed that supplementation has both acute and chronic 
effects improving performance.   
The acute effects of improvement may be due to increased blood and oxygen delivery 
to the working muscles (Blitzer et al., 1996).  The chronic effects were suggested to be due to 
peripheral adaptations.  Vanhatalo et al. (2010) suggested adaptations (along with Bailey et 
al. (2009)) in the skeletal muscle due to the exogenous nitric oxide exposure such as reduced 
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muscle ATP turnover for the same external work rate, which would reduce phosphocreatine 
degradation and accumulation of adenosine diphosphate and inorganic phosphate shown in a 
previous study by this group.  They hypothesized that nitrates could have resulted in more 
efficient maintenance of sarcoplasmic calcium homeostasis and or myosin ATPase activity 
which would reduce the stimulation of oxidative phosphorylation and muscle fatigue 
progression (Vanhatalo et al., 2010).  Vanhatalo et al. (2010) also suggested chronic 
supplementation could have resulted in improvements via changes in muscle oxygen delivery 
and motor unit recruitment.  In addition to increased oxidative metabolic enzyme activity 
(Bailey et al., 2009), Vanhatalo et al. (2010) also concluded that chronic exposure could be 
linked to increased mitochondrial mass based off a previous study which supported that 
mammalian cells increased mitochondrial biogenesis via cGMP pathways when exposed to 
nitric oxide for six days.  These experiments were limited in their conclusions because 
beetroot juice is also high in polyphenols which have previously been linked to a protein 
responsible for mitochondria biogenesis and to increased exercise tolerance (Vanhatalo et al., 
2010).  Consequently, this study used a nitrate depleted beetroot juice placebo to compare 
with the nitrate rich beetroot juice to examine the nitrate dependent effects on oxygen 
availability, vascular activity, and performance.  A control group with just water was also 
used to control for the placebo effect and give comparison of the effects of non-nitrate 
compounds on these variables.  Nonetheless, these experiments still supported that beetroot 
juice improves exercise performance by reducing oxygen cost during submaximal intensity 
exercise (Bailey et al., 2009; Vanhatalo et al., 2010), improving high intensity exercise 
tolerance (Bailey et al., 2009; Vanhatalo et al., 2010), and improving the work rate associated 
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with GET and peak power output during a ramp incremental test to exhaustion (Vanhatalo et 
al., 2010). 
While tests to exhaustion and constant work rate tests showed valid improvements in 
performance, they are not as applicable to competitive situations as simulated time trials.  
Athletic performance is usually based on time of completion in which the work rate is self-
selected.  Time trials have been shown to be more reliable than constant work rates tests to 
exhaustion (Jeukendrup, Saris, Brouns, & Kester, 1996).  Jeukendrup et al. (1996) analyzed 
the performances of five repeated trials of a time trial protocol compared to a continuous 
exercise (at 75% maximal power output) until exhaustion protocol of a similar length 
(approximately one hour) on an electronically braked cycle ergometer.  They observed 
individual coefficients of variance for each subject ranging from 0.8% to 5.8% for the time 
trial and 17.4% to 39.5% for the continuous exercise to exhaustion protocol, respectively 
(Jeukendrup et al., 1996).  In addition, Palmer et al. (1996) found similar variances of 
performance times between the completion of three trials of a 20 km and three trials of a 40 
km time trial (coefficient of variance: 1.1 ± 0.9% and 1.0 ± 0.5%, respectively) on an air-
braked cycle ergometer suggesting that time trials are reliable, reproducible tests.  
Furthermore, significant correlations were observed between time trial performance times 
and performance times during actual road races (r = 0.98) when the 40 km laboratory test 
was compared to a 40 km road race (Palmer, Dennis, Noakes, & Hawley, 1996).  Therefore, 
not only are time trials a reliable measure, but they also may be good predictors and result in 
effective evaluations of field performance.  A time trial of 200 kJ on a isokinetic cycle 
ergometer, one of similar length to that used in this study, has been shown to result in times 
with a low range of variation (coefficient of variation: ± 0.95) (Hickey, Costill, McConell, 
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Widrick, & Tanaka, 1992).  Low levels of variation would lead to a more reliable assessment 
to determine if the treatment is affective in improving performance.  More specifically, 
athletes would be interested in whether the acute supplementation of beetroot juice can help 
improve race performance, thus improving their time and making them more competitive. 
Acute supplementation should be analyzed during a time trial performance test to determine 
this. 
 
Time trial performance.  One double blind crossover study examined the effects of 
acute ingestion of 0.5 L of beetroot juice (6.2 mMol of nitrate) compared to 0.5 L of nitrate 
depleted beetroot juice (~0.0047 mMol of nitrate) in healthy male competitive club cyclists 
(mean age 21± 4 years; similar to subjects in this experiment) on 4 km and 16.1 km time trial 
performance (Lansley et al., 2011).  While oxygen consumption (VO2) did not significantly 
differ between the treatment groups, power output (PO) significantly increased, systolic 
blood pressure decreased, and both 4 km and 16.1 km race performances improved by a 
similar amount with the beetroot juice compared to the placebo (Lansley et al., 2011).  These 
results suggest that it was the nitrates in beetroot juice (supported by elevated plasma nitrite 
levels) that were responsible for improving performance and cycling economy (as displayed 
by higher PO for the same VO2) in events of distances between 4 and 16.1 km (Lansley et al., 
2011).  In addition, these results showed that only an acute dose was needed to improve 
performance even though this dose of 6.2 mMol of nitrate was 4-12 times greater than 40-
100 mg/day (Mensinga, Speijers, & Meulenbelt, 2003), the typical daily dietary intake in the 
United States (Lansley et al, 2011).  Lansley et al. (2011) did recognize a few limitations of 
their study, such as that some compounds that could be responsible for these physiological 
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changes may require nitrate to become activated, in addition to the lack of monitoring the 
diet, hydration status, and quality of sleep of the subjects.  They also did not control for the 
placebo effect or the influence of other non-nitrate beetroot compounds.  In addition to using 
a control containing water, this study also required a twenty-four hour pre-supplemental trial 
log to monitor diet, hydration, and sleep to help draw a more accurate conclusion.  Besides 
these limitations, these results strongly supported that the nitrates in beetroot juice improve 
time trial performance at normoxia.  It is still unknown if dietary nitrates can help improve 
aerobic performance at high altitude or hypoxia.   
Cyclists commonly have to compete in races at moderate to high altitude (Hahn & 
Gore, 2001; Martin et al., 2010).  Because these aerobic performances at high altitude are so 
impaired by hypoxia (Hahn & Gore, 2001; Martin et al., 2010), dietary nitrate oral 
supplementation may be a potential natural and practical mechanism to reduce the 
impairment, increasing performance and making athletes more competitive at high altitude.  
Like the previous example, this study used trained club level cyclists and triathletes during 
acute hypoxic exposure with a similar amount of acute nitrate supplementation to simulate 
closely a real situation in which the competitive athlete just ascends for the race.  The 
recruited subjects likewise had a significant previous experience of cycling and completing 
these races to rule out familiarization bias.  A race of intermediate length (approximately 200 
kJ) was used to tax the aerobic system that is so highly relied on for race performance and 
impaired by high altitude/hypoxic exposure (Hahn & Gore, 2001).  Size of the subject can 
often affect results in the field due to factors such as wind resistance (Hahn & Gore, 2001; 
Smith, Davison, Balmer, & Bird, 2001); therefore, energy expenditure was used to factor out 
this influence and make it more applicable to simulated competition. 
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Similar to the Lansley et al. (2011) study, oxygen consumption and race time were 
measured along with heart rate and systemic blood pressure to analyze potential 
improvements, but the ability to measure plasma nitrite concentration via chemiluminescence 
technique was not accessible or feasible for this experiment.  Based on previous research that 
has shown that hypoxic and acidic environments enhance nitric oxide production (Modin et 
al., 2001), the amount of nitrates in red beetroot juice that have been shown to be effective 
during exercise at normoxia should also be effective during exercise at hypoxia, a more 
hypoxic and acidic environment than exercise at normoxia.  A similar amount of nitrate 
content via the same brand of beetroot juice used in the Lansley et al. study at normoxia was 
used in this experiment to examine its effects on performance at hypoxia.  In conclusion, 
there is evidence that red beetroot juice helps improve aerobic exercise performance at 
normoxia; however, it is still unknown if red beetroot juice improves aerobic exercise 
performance at hypoxia. 
 
Conclusion 
 Overall, previous research has shown that supplemental pulmonary vasodilators, such 
as PDE-5 inhibitors, are capable of increasing arterial blood oxygen saturation and blood 
oxygen delivery that are reduced as a result of hypoxic pulmonary vasoconstriction (Ghofrani 
et al., 2004; Hsu et al., 2006; Richalet et al., 2005).  These PDE-5 inhibitors have also been 
shown to improve aerobic exercise performance at high altitude and hypoxia (Ghofrani et al., 
2004; Hsu et al., 2006; Richalet et al., 2005).  While exogenous nitrite and nitric oxide have 
been reported to cause pulmonary vasodilation (Ingram et al., 2010; Scherrer et al., 1996; 
Zuckerbraun et al., 2011), dietary nitrates have only been tested and shown to cause 
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vasodilation in the systemic circulation (Kapil et al., 2010; Webb et al., 2008).  Dietary 
nitrates, such as red beetroot juice, have also been shown to increase athletic aerobic exercise 
performance (Bailey et al., 2009; Lansley et al., 2011; Vanhatalo et al., 2010), but this has 
only been tested at normoxia.  It is unknown if dietary nitrates can decrease arterial blood 
oxygen desaturation that results from hypoxia-induced pulmonary vasoconstriction and lead 
to an increase in aerobic exercise performance at hypoxia or high altitude.  The purpose of 
this study was to determine the effect of short-term red beetroot juice supplementation on 
systemic blood pressure, exercising arterial blood oxygen saturation, and acute aerobic 
(approximately 200 kJ) time trial performance during acute hypoxic exposure (simulated 
high altitude (4300 m)) in male club level cyclists and triathletes. 
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Experiment 
Methodology 
It is unknown if dietary nitrates, such as red beetroot juice, can decrease the arterial 
blood oxygen desaturation that results from hypoxic pulmonary vasoconstriction and lead to 
an increase in aerobic exercise performance at hypoxia or high altitude.  The purpose of this 
study was to determine the effect of short-term red beetroot juice supplementation on 
systemic blood pressure, exercising arterial blood oxygen saturation, and acute aerobic 
(approximately 200 kJ) time trial performance during acute hypoxic exposure (simulated 
high altitude (4300 m)) in male club level cyclist and triathletes. 
 
Subjects.  Nine healthy trained competitive male cyclists and triathletes (18-30 years 
old) were recruited from the Appalachian State University Cycling team and local cycling 
community to insure consistent time trial performances and limit the familiarization effect of 
cycling throughout the experiment.  All athletes had at least one year of competitive 
experience and had been currently undergoing regular training sessions of at least three days 
per week for the last eight weeks.  Additionally, all participants lived at 1300 m (4000 ft) and 
below for the past six months with occasional traveling excursions above 1300 m (4000 ft).  
Individuals who made extended sojourns (longer than 2 days) above 4000 feet over this time 
period were excluded from the study.  Individuals were excluded from this study if they had 
a previous or current history of one or more of the following: smoking, pulmonary 
hypertension, high altitude pulmonary edema, cardiopulmonary disease, cardiovascular 
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disease or a current physical condition that impaired physical activity.  Females were not 
allowed to participate in this study due to the confounding factor of possible hormone linked 
nitrate processing (Kapil et al., 2010).  Participants were not allowed to use aspirin, 
ibuprofen, or compounds containing acetaminophen during the study.  No subjects 
previously used or were currently using dietary supplements in the past month for fat soluble 
supplements or past week for water soluble supplements.   
Before participating in the exercise tests, subjects completed a health history 
questionnaire and an ACSMAHA Screening Questionnaire along with a training history to 
examine past training status and current training intensity, volume, and level of competition.  
Height, weight, and blood pressure of each subject were measured before he began the 
exercise tests. 
All participation was voluntary.  After the procedures, risks, and benefits of the study 
were explained, all subjects gave their written informed consent to participate.  This study 
was approved by the Institutional Review Board of Appalachian State University prior to its 
implementation. 
 
Research design. 
General study design.  During the first visit, all subjects underwent an initial 
screening and a pre-supplementation test of initial aerobic cycling fitness (VO2 maximum 
test to exhaustion) along with a practice approximately 200 kJ time trial.  All subjects then 
returned on three more occasions to perform one approximately 200 kJ experimental cycling 
time trial using a different treatment each visit.  The treatments were ingested 2.5 hours 
before the test and contained 70 ml of organic beetroot juice (BR), 70 ml of organic nitrate-
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depleted beetroot juice (PL) (both similar to that used in a study by Lansley et al. (2011)), or 
70 ml of water (CO).  Treatments were administered in a double blind, randomly assigned, 
crossover design.  Subjects and investigators were blinded to the treatments.  The subjects 
were not able to discriminate between the beetroot juice and the placebo due to similar color, 
taste, texture, and odor (Lansley et al., 2011).  Pulmonary, cardiovascular, and metabolic 
measurements in addition to performance results were examined throughout all three 
performance trials.  Each experimental trial was separated by a washout period of at least 
forty-eight hours but no more than one week.  All practice tests and experimental tests for 
each subject were done at the same time of day with the same number of days between trials.   
 
Hypoxic exposure.  During all of the experimental performance tests, each subject 
was acutely exposed to hypoxic gas similar to the set up used in a previous study (Morris, 
Kearney, & Burke, 2000).  The hypoxic gas was released from a gravimetrically certified G 
sized cylinder through a Hans Rudolph mouth piece (7600, V2; Hans Rudolph Inc., Kansas 
City, MO) containing a two-way non-rebreathing Hans Rudolph value connected via 3.18 cm 
I.D. plastic tubing to the gas reservoir (Morris et al., 2000).  The reservoir was a 120 L 
meteorological balloon modified to allow simultaneous filling from the cylinder to allow gas 
delivery to the subject at ambient barometric pressure (Morris et al., 2000).  The breathing 
gas contained a fraction of inspired oxygen (FIO2) of 12.97-13.02% (partial pressure of 
oxygen in the inspired gas of about 88.4 Torr).  The hypoxic gas was measured before each 
test to insure oxygen content remained consistent throughout all exercise tests.  Subjects 
wore a nose plug to ensure all exchanged gases were measured.   
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Intervention.  Three supplementation treatments were used, and each subject 
experienced each treatment.  The supplemental fluid contained either 70 ml of organic 
beetroot juice (BR) (containing ~0.4g, 6.45 mMol of nitrate; Beet it Sport Stamina Shot, 
James White Drinks Ltd., Ipswich, UK), 70 ml of organic nitrate depleted beetroot juice (PL) 
(containing ~0.048 mMol of nitrate; Beet it Sport Stamina Shot Placebo, James White Drinks 
Ltd., Ipswich, UK), (similar to that used in a study by Lansley et al. (2011)), or 70 ml of 
water (CO).  The organic beetroot juice was placed through an ion exchange resin selective 
for nitrate ions to create the nitrate-depleted beetroot juice placebo (Lansley et al., 2011).  
The PL was otherwise similar to the beetroot juice in color, taste, texture, and odor (Lansley 
et al., 2011). 
Subjects were contacted via phone or email prior to the first pre-supplementation visit 
and notified of the pre-participation requirements.  All subjects were requested to maintain a 
consistent diet, training program, and physical activity schedule throughout the experiment.  
In addition, they were instructed to consume similar meals and perform a similar degree of 
physical activity the day before and the day of the performance test for all three experimental 
trials.  They were provided with a list of foods which they were required to abstain from 
eating since they are high in nitrate and antioxidant content.  Subjects were asked to abstain 
from caffeine and alcohol twenty-four hours prior to each performance test.  They were 
required to keep a log of all fluids and food consumed along with all physical activity 
performed and quality and quantity of sleep obtained twenty-four hours before each visit.  
They were instructed to avoid strenuous physical activity (no more than thirty minutes at 
equal to or greater than 60% maximum heart rate) twenty-four hours before each 
performance trial.  Participants were told to drink one liter of fluids the night before and one 
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liter of fluids the morning of each visit.  Subjects were required to abstain from consuming 
any foods or fluids, except water, four hours prior to each visit.  Two hours prior to arrival, 
the subject consumed a standardized 460 kcal meal consisting of complex and simple 
carbohydrates (two Chocolate Chip Clif Bars, Clif Bar & Company, Emeryville, CA) and 
one liter of water.  Upon arrival, they were not allowed to eat or drink (other than the 
treatment fluid) three hours before the performance trial.  Furthermore, they were not 
allowed to drink or consume any fluids or food after the treatment was ingested until after the 
performance trial was complete.  Finally, participants were not allowed to use chewing gum 
or anti-bacterial mouthwash forty-eight hours prior to the performance test since these are 
known to destroy the oral bacteria necessary for the conversion of nitrate to nitrite (Govoni, 
Jansson, Weitzberg, & Lundberg, 2008).  Subjects were reminded of these requirements at 
the end of each visit to insure consistent results for the following visits. 
 
Experimental procedure. 
Pre-supplementation period.  On the same day as the screening, participants 
performed both a VO2 maximum test to exhaustion and a practice time trial under a protocol 
used in a previous study (Morris, Shafer, Fairbrother, & Woodall, 2011).  All tests were 
performed using an electronically braked cycle ergometer (Lode Excalibur Sport Cycle 
Ergometer, Groningen, Holland) adjusted to the dimensions of the subject’s own bicycle.  
These pre-supplementation tests were completed under normoxic conditions.  For the warm 
up and VO2 max test, the cycle ergometer was placed in a manual mode that allowed the 
investigator to control manually the timing and application of the workloads.  All warm-ups 
and tests where manually controlled by the same investigator.  The warm-up consisted of a 
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total of ten minutes starting at a power output of (3* mass (kg))-100 W for each subject 
which then increased by 10 W every minute (Morris et al., 2011).  Subjects rested for five 
minutes while equipment was prepared for the graded exercise test.  During the VO2 max 
test, each stage was one minute long (Morris et al., 2011).  The power output for the first 
stage was set at: W=3* mass (kg), and each subsequent stage was increased by 0.3 W * mass 
(kg) (Morris et al., 2011).  Oxygen consumption, respiratory exchange ratio (RER), and heart 
rate were monitored in fifteen second intervals throughout the test.  Maximum oxygen 
consumption (VO2 max) was determined based on these variables.  Subjects were allowed to 
cool down with a comfortable load specified by the subject and to walk around while the 
equipment was prepared for the practice performance trial.  
The practice time trial performance test was performed on the same cycle ergometer 
fifteen to twenty minutes after the maximum test.  The practice time trial was used to allow 
the subjects to become familiar with manually adjusting the work rate.  A warm-up was not 
necessary before this test.  The Lode cycle ergometer was set up to allow manual work rate 
changes.  Subjects were encouraged to complete the trial as fast as they could.  The length of 
the time trial was determined based on the subject’s body weight (Length = 2.5 kJ / kg of 
body weight).  The only feedback that the subjects received was the work performed 
(distance) displayed by the digital readout on the Lode ergometer (16.4 kJ / 1 km); subjects 
were blinded to the actual work rates, time, power output, or any other performance 
measures.  Subjects were not informed of their results on any test during the study.  Subjects 
received similar verbal encouragement by the test administrators throughout all tests. 
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Supplementation period.  Each subject returned to the Vascular, Biological, and 
Autonomic Studies Laboratory at Appalachian State University, room 186C, University Hall, 
on three separate occasions of equal spacing at the same time of day.  The first experimental 
performance trial was at least forty-eight hours to no more than one week after the pre-
supplementation practice trial.  One time trial was completed with each treatment, and each 
trial was separated by at least forty-eight hours to no more than one week to allow for a 
washout of the previous treatment.  The number of days between each trial was kept 
consistent during all trials for each subject.  This time was used to control for variability, 
detraining, fatigue, and to insure for an effective washout period since the half-life of nitrates 
is 5-8 hours in the body (Hord et al., 2009).  The treatment order was randomly assigned and 
kept in a mostly double blind manner.  Participants arrived at the lab three hours before each 
performance test and were placed in a seated position and allowed to rest quietly for fifteen 
minutes.  Two hours and forty-five minutes before the warm-up, systemic blood pressure was 
measured at the right brachial artery.  Two hours and thirty minutes before the warm-up, 
subjects were required to drink 70 ml of the treatment fluid.  This time of 2.5 hours prior to 
the warm-up was used since previous studies have determined that the plasma nitrite and 
vasodilatory effects of dietary nitrates peak after 2.5-3 hours of ingestion of the nitrates 
(Kapil et al., 2010; Webb et al., 2008).  Subjects were allowed to leave the lab provided that 
they did not consume any food or fluids or undergo any physical activity.  They were 
required to return to the lab 2 hours later to undergo a 15 minute seated resting period before 
blood pressure measurements were taken.  Fifteen minutes before the warm-up, resting 
systemic blood pressure was measured again, and instructors and subjects prepared for the 
warm-up.  The warm-up lasted ten minutes and began at 50 W below the starting work rate 
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of each subject’s VO2 max test (Morris et al., 2011) on the same Lode cycle ergometer used 
in the pre-supplementation period.  After one minute, the power output was increased by 10 
W and continued to increase by 10 W for five minutes (Morris et al., 2011).  Subjects then 
remained at the wattage reached (starting wattage of the VO2 max test) for five more minutes 
(Morris et al., 2011).  Subjects then rested for five minutes while the equipment was prepared 
for the performance test, and another systemic blood pressure measurement was taken at the 
end of the five minute rest period.  The Lode ergometer was placed in a mode to allow for 
manual adjustments of work rates.  This set up was done to simulate an actual time trial race.  
Following the five minute rest period and blood pressure measurement, subjects became 
accustomed to breathing the hypoxic gas for three minutes while sitting on the cycle 
ergometer.  Eighteen minutes past the warm-up start time, subjects started motionless in a 
gated start style waiting on a cue from the lab technician to begin the performance test under 
the hypoxic conditions.  Subjects were able to change work rates as desired.  Similar to the 
practice trial, subjects received feedback only on their work completed; time, speed, and 
power output were withheld.  The investigators gave verbal encouragement similar to that in 
the pre-supplementation trial.  VO2 and RER were monitored with the metabolic cart in the 
same way as the VO2 max test.  Blood oxygen saturation, elapsed time, and heart rate were 
recorded after 0.0, 0.25, 0.50, 0.75, and 1.00 of the total kilojoules were completed.  After 
completion of the trial, subjects were allowed to remove the mouth piece and nose clip and 
cool down manually adjusting the work rate. 
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Means of data collection. 
Pre-supplementation measurements.  At the first visit before the VO2 max test, the 
same investigator measured the height and weight of each subject using the standard beam 
scale (Health o Meter Professional Standard Beam Scale with Height Rod 402KL, North 
Shore Care Supply, Northbrook, IL) in centimeters and kilograms, respectively.  During the 
VO2 max test, expired respiratory gases were collected continuously, and the gas 
concentrations were analyzed for oxygen consumption and carbon dioxide production by the 
metabolic cart (Parvomedics Truemax 2400, Consentius Technologies, Sandy, UT).  Oxygen 
consumption (VO2), heart rate, and respiratory exchange ratio (RER) were measured and 
averaged over fifteen second intervals by the metabolic cart.  VO2 max was measured as the 
highest reported oxygen consumption value with the fulfillment of three criteria: a plateau in 
oxygen consumption with an increase in work rate, an RER greater than 1.15, and a heart rate 
similar to the age-estimated maximum heart rate for the subject (220-age) (Bassett & 
Howley, 2000).  The metabolic cart was calibrated according to the manual before each use.  
The age, height, weight, and maximum oxygen consumption for the nine subjects were 
measured and reported as (mean ± SD) 
 
Supplementation measurements.  Before each performance trial, systemic blood 
pressure of the right brachial artery was measured using the same manual aneroid 
sphygmomanometer and stethoscope (Prosphyg 775, Series sphygmomanometer and 
Adscope stethoscope, American Diagnostic Corporation, Hauppauge, NY) by the same 
investigator for each subject.  Systolic (SP) and diastolic (DP) blood pressure were 
determined by the sphygmomanometer and used to estimate the mean arterial pressure 
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(MAP) using the standard equation: MAP= 2/3 DP + 1/3 SP.  Blood pressure was measured 
three times: before the supplement was ingested, two hours and fifteen minutes after the 
supplement was ingested before the warm-up, and two hours and forty minutes after the 
supplement was ingested after the warm-up.  Blood oxygen saturation and heart rate were 
measured after 0.00, 0.25, 0.50, 0.75 and 1.00 of the total kilojoules were completed using a 
pulse oximeter that was clipped to the subject’s earlobe (Nonin Digital Handheld Pulse 
Oximeter, 8500; Nonin Medical Inc., Plymouth, MN).  Completion time was measured using 
the timer on the metabolic cart at the end of each segment and at the end of each performance 
time trial (0.25, 0.50, 0.75, and 1.00 of the total kilojoules completed).  Average work rate 
(W) for each segment and time trial was determined based on the distance completed (Lode 
cycle ergometer: 16 kJ/ 1 km) and the time to complete each segment and total time trial.  
Average oxygen consumption (ml/min) was determined for each segment (0.25, 0.50, 0.75, 
and 1.00) and averaged to calculated average oxygen consumption for each time trial.  Mean 
cycling economy was determined as average work rate / average oxygen consumption 
(J*min-1/ml*min-1) during each time trial.  All values were reported as mean ± SD. 
 
Statistical analysis.  Two-Way Repeated Measures Group by Treatment by Time 
Analysis of Variance (ANOVA) was used to assess the effects of treatment (BR, PL, and 
CO), time, and the interaction of treatment and time on systolic blood pressure, diastolic 
blood pressure, and mean arterial pressure at three time points (before ingestion, after 
ingestion before the warm-up, and after the warm-up), on blood oxygen saturation at 0.00, 
0.25, 0.50, 0.75, and 1.00 of the total kilojoules completed, and on completion time and work 
rate for 0.25, 0.50, 0.75, and 1.00 of the total kilojoules completed.  One-Way Repeated 
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Measures Group by Treatment Analysis of Variance was used to assess the effects of 
treatments on the percent change in systolic, diastolic, and mean arterial blood pressure from 
before ingestion to after ingestion before the warm-up and from before ingestion to after the 
warm-up and on average time trial completion time, average work rate, average oxygen 
consumption, and average cycling economy of the time trial cycling tests.  Following a 
significant F-ratio, specific differences between treatments were explored using Sidak post-
hoc analyses using Cohen’s F2.  Statistical significance was set at P≤ 0.05.  A Paired Samples 
T-test was used to compare the percent difference in time trial completion time between BR 
and CO to the percent difference in time trial completion time between PL and CO.  A 
Pearson r correlation was conducted to examine the relationship between average oxygen 
consumption and time trial completion time.  With relatively small sample size, rather large 
differences may not reach statistical significance and result in type II error with other 
secondary variables. Therefore, effect sizes (partial η2, which represents the proportion of 
total variation attributable to the factor, partialing out other factors from the total nonerror 
variation) are reported as an additional statistical parameter to aid the reader in interpretation 
of the findings.  All statistical analysis was performed using statistical analysis software 
(SPSS, Version 20.0, SPSS Inc., Chicago, IL). 
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Results    
Subjects.  Nine healthy competitive male cyclists and triathletes (mean ± SD: age 22 
± 4 years, height 181 ± 8 cm, body mass 73.80 ± 8.3 kg, VO2max 66.7 ± 8.6 ml/kg/min) 
participated in the study.  The beetroot juice (BR), placebo (PL), and control (CO) 
supplementation was well tolerated with no reported harmful side effects.  Hypoxic gas 
exposure was well tolerated by all subjects.  Data was scanned for compliance with the diet, 
physical activity, and sleep requirements.  Although there were slight variations in physical 
activity and diet, the data moved in no direction that suggested an effect of compliance on 
exercise performance. 
 
Blood pressure.  Blood pressure measurements were taken before ingestion (before 
ingestion), 2 hours and 15 minutes after ingestion before the warm-up (after ingestion before 
the warm-up), and 2 hours and 45 minutes after ingestion after the warm-up (after the warm-
up).  Systolic blood pressure, diastolic blood pressure, and mean arterial pressure for each 
time point and each treatment are shown in Table 1 on page 61.  No significant main effects 
due to treatment were observed at any of the measurement times in systolic blood pressure 
(BR vs PL, P=0.24; BR vs CO, P=0.35; PL vs CO, P=0.95; Effect Size=0.25, Observed 
Power=0.46), diastolic blood pressure (BR vs PL, P=0.99; BR vs CO, P=0.99; PL vs CO, 
P=0.98; Effect Size=0.01, Observed Power=0.06), and mean arterial pressure (BR vs PL, 
P=0.96; BR vs CO, P=0.62; PL vs CO, P>0.99; Effect Size=0.04, Observed Power=0.83).  
Significant main effects due to time were observed in systolic blood pressure (P<0.01, Effect 
Size=0.70, Observed Power>0.99) and mean arterial pressure (P=0.02, Effect Size=0.51, 
Observed Power=0.77).  No significant main effects due to time were observed in diastolic 
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blood pressure (P=0.07, Effect Size=0.28, Observed Power=0.52).  Significant increases in 
blood pressure from before ingestion to after the warm-up were revealed in systolic blood 
pressure under the PL treatment (PL, P=0.01); however, systolic blood pressure did not have 
significant increases under the BR and CO treatments (BR, P=0.26; CO, P=0.10).  Diastolic 
blood pressure and mean arterial pressure increased, but these increases were not statistically 
significant (Diastolic: BR, P=0.05; PL, P=0.98; CO, P=0.65; MAP: BR, P=0.06; PL, 
P=0.26; C, P=0.28).  Significant increases in blood pressure from after ingestion before the 
warm-up to after the warm-up were observed in systolic blood pressure under the BR and PL 
treatments (BR, P=0.02; PL, P=0.01) and in mean arterial pressure under the BR treatment 
(BR, P=0.04); but, these increases were not significant in systolic blood pressure under the 
control treatment (CO, P=0.07) and in mean arterial pressure under the PL and CO 
treatments (PL, P=0.07; CO, P=0.45).  These increases were also not significant in diastolic 
blood pressure under the BR and CO treatments and resulted in no change under the PL 
treatment (BR, P=0.15; PL, P>0.99; CO, P=0.99).  Non-significant decreases from before 
ingestion to after ingestion before the warm-up were observed in systolic blood pressure 
under the BR, PL, and CO treatments (BR, P=0.08; PL, P=0.32; CO, P=0.59) and mean 
arterial pressure under the PL treatment (PL, P=0.93).  Non-significant increases from before 
ingestion to after ingestion before the warm-up were observed in diastolic blood pressure 
under the BR, PL, and CO treatments (BR, P=0.50; PL, P=0.95; CO, P=0.38) and in mean 
arterial pressure under the BR and CO treatments (BR, P=0.99; CO, P=0.61).  No significant 
interaction between treatment and time was observed in systolic blood pressure (P=0.74, 
Effect Size=0.06, Observed Power=0.15), diastolic blood pressure (P=0.09, Effect Size=0.22, 
Observed Power=0.58), or mean arterial pressure (P=0.36, Effect Size=0.12, Observed 
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Power=0.31).  Percent change in blood pressure from before ingestion to after ingestion 
before the warm-up was observed to be non-significant for each of the three treatments in 
systolic blood pressure (BR vs PL, P=0.93; BR vs CO, P=0.61; PL vs CO, P=0.94; Effect 
Size=0.07, Observed Power=0.16), diastolic blood pressure (BR vs PL, P=0.72; BR vs CO, 
P=0.98; PL vs CO, P=0.72; Effect Size=0.09, Observed Power=0.16), and mean arterial 
pressure (BR vs PL, P=0.93; BR vs CO, P=0.99; PL vs CO, P=0.66; Effect Size=0.06, 
Observed Power=0.11).  Percent change in blood pressure from before ingestion to after the 
warm-up was observed to be non-significant for each of the three treatments in systolic blood 
pressure (BR vs PL, P=0.66; BR vs CO, P=0.87; PL vs CO, P=0.97; Effect Size=0.08, 
Observed Power=0.15), diastolic blood pressure (BR vs PL, P=0.20; BR vs CO, P=0.31; PL 
vs CO, P=0.73; Effect Size=0.27, Observed Power=0.49), and mean arterial pressure (BR vs 
PL, P=0.46; BR vs CO, P=0.63; PL vs CO, P=0.80; Effect Size=0.17, Observed 
Power=0.29). 
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Table 1 
Blood Pressure Responses to Treatments 
 
Blood Pressure Measurement (mmHg) Beetroot Juice Placebo Control 
Systolic Blood Pressure     
Before Ingestion  123 ±7  117 ± 4  118 ± 8 
After Ingestion Before Warm-Up  117 ± 9  113 ± 8  115 ± 10 
After Warm-Up # 128 ± 7 *# 125 ±7  125± 10 
% Change From Before Warm-Up to After Ingestion Before Warm-Up  -5 ± 5 % -3 ± 5 % -2 ± 5 % 
% Change From Before Warm-Up to After Warm-Up 4 ± 7 % 7 ± 5 % 6 ± 7 % 
    
Diastolic Blood Pressure     
Before Ingestion 74 ± 7 78 ± 9 76 ± 8 
After Ingestion Before Warm-Up 78 ± 6 79 ± 9 79 ± 6 
After Warm-Up 84 ± 6 79 ± 12 80 ± 8 
% Change From Before Warm-Up to After Ingestion Before Warm-Up 5 ± 11 % 1 ± 5 % 4 ± 9 % 
% Change From Before Warm-Up to After Warm-Up 14 ± 14 % 1 ± 11 % 6 ± 16 % 
    
Mean Arterial Pressure     
Before Ingestion 90 ± 6 91 ± 5 90 ± 6 
After Ingestion Before Warm-Up  91 ± 6  90 ± 8  91 ± 5 
After Warm-Up # 98 ± 6 95 ± 8  95 ± 6 
% Change From Before Warm-Up to After Ingestion Before Warm-Up 1 ± 6 % -1 ± 5 % 1 ± 3 % 
% Change From Before Warm-Up to After Warm-Up 9 ± 10 % 4 ± 6 % 6 ± 9 % 
 
*P<0.05 Compared to before ingestion for that treatment. 
#P<0.05 Compared to after ingestion before the warm-up for that treatment. 
All values: Mean ± SD. 
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Time trial results. 
Performance.  The data was tested for an order effect.  No significant differences 
were found between the three time applications of the time trial tests (Test 1, 897.11 ± 
153.81 sec; Test 2, 873.22 ± 140.59 sec; Test 3, 895.67 ± 146.20 sec) (1 vs 2, P=0.83; 1 vs 3, 
P>0.99; 2 vs 3, P=0.35; Effect Size=0.06, Observed Power=0.10).  Results for total 
completion time based on treatment are displayed in Figure 1 on page 63.  No significant 
differences in time trial completion times were observed when comparing the three 
treatments (BR vs PL, P=0.33; BR vs CO, P=0.87; PL vs CO, P=0.50; Effect Size=0.16, 
Observed Power=0.28).  Completion time for each treatment was: BR: 911.78 ± 163.07 sec, 
PL: 865.78 ± 131.02 sec, and CO: 888.44 ± 142.32 sec.  Results for completion time for each 
segment under each treatment are displayed in Table 2 on page 64.  There also were no 
differences observed in performance during any of the time trial segments due to treatment; 
however, there was a significant difference due to the portion of the time trial completed.  
There was a significant increase in segment completion time for the 0.00-0.25 segment 
compared to all other segments in the BR treatment only (BR: 0.00-0.25 vs 0.25-0.50, 
P<0.01; vs 0.50-0.75, P=0.03; vs 0.75-1.00, P=0.02; Effect Size=0.57, Observed 
Power>0.99).  There was no significant effect due to the interaction of treatment and portion 
of the time trial completed (P=0.11, Effect Size=0.24, Observed Power=0.45).  Finally, no 
significant differences were observed when comparing the percent difference in completion 
time between BR and CO to the percent difference in completion time between PL and CO 
(2.32 ± 10.57% and -2.43 ± 5.42%; respectively, P=0.12, Effect Size=0.28, Observed 
Power=0.34). 
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Figure 1. Time trial completion time. 
All values: Mean ± SD.
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Table 2 
Completion Times for Each Segment of the Time Trial 
 
 
Segment Beetroot Juice Placebo Control 
 
0.00-0.25  * 253.33 ± 39.65 sec 232.00 ± 50.21 sec 222.89 ± 44.75 sec 
0.25-0.50  221.89 ± 45.56 sec 206.11 ± 31.67 sec 215.22 ± 40.45 sec 
0.50-0.75  223.56 ± 50.39 sec 214.44± 40.69 sec 227.56 ± 42.14 sec 
0.75-1.00  213.00 ± 35.20 sec 213.22 ± 38.61 sec 222.78 ± 31.72 sec 
 
 
* P<0.05.  From all other segments for BR treatment only. 
All values: Mean ± SD. 
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Results for average work rate based on treatment are displayed in Figure 2 on page 66.  
The treatment did not have significant effects on the average work rate for each time trial (BR vs 
PL, P=0.27; BR vs CO, P=0.91; PL vs CO, P=0.33; Effect Size=0.18, Observed Power=0.32).  
Average work rate under each treatment was as follows: BR, 206.8 ± 20.0 W; PL, 217.5 ± 15.1 
W; and CO, 211.4 ± 19.3 W.  Results for work rate for each segment completed of the time trial 
under each treatment are displayed in Table 3 on page 67.  There were also no differences 
observed in work rate during any of the time trial segments due to treatment; however, there was 
a significant difference due to the portion of the time trial completed.  There was a significant 
decrease in work rate for the 0.00-0.25 segment compared to all other segments in the BR 
treatment only (BR: 0.00-0.25 vs 0.25-0.50, P=0.01; vs 0.50-0.75, P=0.03; vs 0.75-1.00, P=0.02; 
Effect Size=0.64, Observed Power=0.98).  There was no significant effect due to the interaction 
of treatment and portion of the time trial completed (P=0.13, Effect Size=0.23, Observed 
Power=0.75).  
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Figure 2. Work rate during the time trial. 
All values: Mean ± SD. 
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Table 3 
Work Rates for Each Segment of the Time Trial 
 
 
Segment Beetroot Juice Placebo Control 
 
0.00-0.25  * 184.71 ± 13.37 W 206.07 ± 37.19 W 219.61 ± 30.12 W 
0.25-0.50  212.11 ± 23.64 W 225.93 ± 19.68 W 218.18 ± 25.73 W 
0.50-0.75  213.06 ± 27.00 W 219.94 ± 22.25 W 207.29 ± 20.83 W 
0.75-1.00  217.46 ± 23.65 W 218.22 ± 28.25 W 207.19 ± 21.05 W 
 
 
* P<0.05.  From all other completion points for BR treatment only. 
All values: Mean ± SD. 
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Physiological.  Treatment had no significant effect on arterial blood oxygen saturation at 
any portion of the trial completed during the time trial (BR vs PL, P=0.69; BR vs CO, P>0.99; 
PL vs CO, P=0.83; Effect Size=0.05, Observed Power=0.11).  There was a significant effect for 
the measurement point with regard to blood oxygen saturation (P<0.01, Effect Size=0.95, 
Observed Power>0.99).  Oxygen saturations at each completion point for each treatment are 
displayed in Table 4 on page 69.  Blood oxygen saturation was significantly higher at the starting 
point (0.00) of the time trial versus all other completion points under all three treatments (BR: 
0.00 vs 0.25, 0.50, 0.75, 1.00 P<0.01; Effect Size=0.88, Observed Power>0.99; PL: 0.00 vs 0.25, 
0.50, 0.75, 1.00 P<0.01; Effect Size=0.92, Observed Power>0.99; CO: 0.00 vs 0.25, 0.50, 0.75, 
1.00 P< 0.01; Effect Size=0.91, Observed Power>0.99).  Significant decreases in blood oxygen 
saturation were also observed between the 0.25 completion point and the 1.00 completion point 
under the PL treatment (P=0.01).  No significant interaction between treatment and portion of 
time trial completed (P=0.27, Effect Size=0.15, Observed Power=0.31) was observed. 
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Table 4 
Arterial Blood Oxygen Saturation of Cyclists During the Time Trials 
 
 
Completion Point Beetroot Juice Placebo Control 
 
0.00  * 93 ± 3 % * 94 ± 3 % * 94 ± 4 % 
0.25  76 ± 4 % # 76 ± 5 % 76 ± 3 % 
0.50  74 ± 3 % 74 ± 6 % 74 ± 4 % 
0.75  73 ± 3 % 71± 4 % 73 ± 4 % 
1.00  74 ± 7 %  70 ± 3 % 73 ± 5 % 
 
 
* P<0.05.  From all other completion points for that treatment. 
# P<0.05.  From 1.00 completion point of the same treatment. 
All values: Mean ± SD 
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Additionally, there were no significant effects due to treatment observed in average 
oxygen consumption during the time trial between any of the three treatments (BR vs PL, 
P=0.99; BR vs CO, P=0.99; PL vs CO, P=0.99; Effect Size=0.01, Observed Power=0.58).  
Average oxygen consumption under each treatment was as follows: BR, 2230.7 ± 211.9 
ml/min; PL, 2252.5 ± 140.5 ml/min; and CO, 2245.8 ± 154.9 ml/min.  Average oxygen 
consumption was not strongly correlated to time trial completion time (r=0.2, P=0.32).  
Finally, there were no significant treatment effects on mean cycling economy (Work Rate / 
Oxygen Consumption (J*min-1/ml*min-1) during the time trial between any of the three 
treatments (BR vs PL, P=0.90; BR vs CO, P> 0.99; PL vs CO, P=0.77; Effect Size=0.04, 
Observed Power=0.09).  Results for mean cycling economy based on treatment are displayed 
in Figure 3 on page 71.  Mean cycling economy for each treatment was as follows: BR, 5.6 ± 
0.7 J*min-1/ml*min-1 of oxygen consumed; PL, 5.8 ± 0.4 J*min-1/ml*min-1 of oxygen 
consumed; and CO, 5.7 ± 0.7 J*min-1/ml*min-1 of oxygen consumed. 
 
 
 
 
71 
 
Figure 3. Cycling economy during the time trial. 
All values: Mean ± SD.
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Test of Research Hypotheses 
1. Systolic blood pressure, diastolic blood pressure, and mean arterial pressure would be 
decreased under the beetroot juice treatment compared to the placebo and control.  
The hypothesis was rejected.  No significant differences in systolic blood pressure, 
diastolic blood pressure, and mean arterial pressure were observed due to treatment 
(P>0.05). 
2. Time trial cycling performance time would be decreased under the beetroot juice 
treatment compared to the placebo and control.  The hypothesis was rejected.  No 
significant difference in completion times was observed due to treatment (P>0.05). 
3. Arterial blood oxygen saturation would be increased under the beetroot juice 
treatment compared to the placebo and control.  The hypothesis was rejected.  No 
significant difference in blood oxygen saturation was observed due to treatment 
(P>0.05).
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Discussion 
The purpose of this study was to determine the effect of short-term red beetroot juice 
supplementation on systemic blood pressure, exercising arterial blood oxygen saturation, and 
acute aerobic (approximately 200 kJ) time trial performance during acute hypoxic exposure 
(simulated high altitude (4300 m)) in male club level cyclist and triathletes.  The results 
showed that beetroot juice did not have a significant effect on systemic blood pressure, 
exercising arterial blood oxygen saturation, and time trial cycling performance time during 
hypoxic exposure compared to placebo and control. 
 
Blood pressure.  Blood pressure was taken before ingestion (before ingestion), 2 
hours and 15 minutes after ingestion before the warm-up (after ingestion before the warm-
up), and 2 hours and 45 minutes after ingestion at the end of a 5 minute rest period following 
the warm-up (after the warm-up).  It was hypothesized that beetroot juice supplementation 
would result in a decrease in systolic blood pressure, diastolic blood pressure, and mean 
arterial pressure; however, acute beetroot juice supplementation did not have an effect on 
systolic blood pressure, diastolic blood pressure, and mean arterial pressure when compared 
to placebo and control in the current study.  This hypothesis was rejected.  There was a 
statistically significant observed increase in systolic blood pressure under the beetroot and 
placebo treatments and in mean arterial pressure under the beetroot treatment when 
comparing the measurement points from after ingestion before the warm-up to after the 
warm-up.  A rise in systolic blood pressure is a typical response during aerobic exercise 
(Filipovsky, Ducimetiere, & Safar, 1992).  Systolic blood pressure also rose in the control 
group, and mean arterial pressure also rose in the placebo and control groups, but these 
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changes were not statistically significant, possibly because of large variance in the data.  An 
increase in blood pressure from before ingestion to after the warm-up would have also been 
expected.  All systolic blood pressures rose over this period, but possibly due to large 
standard deviations, the only blood pressure increase that was found statistically significant 
was in systolic blood pressure under the placebo treatment.  Additionally, no significant 
differences were observed when comparing before ingestion to after ingestion before the 
warm-up.  Systolic blood pressure decreased under all treatments with the largest decrease 
observed in the beetroot juice treatment group, but these decreases did not result in statistical 
significance under any treatment.  Some of the systolic pressure reduction in all treatment 
groups could be due to the majority of the subjects deciding to remain seated in the lab 
following the ingestion of the treatment and before the pre-warm-up blood pressure 
measurement, but large standard deviations and several limitations could have resulted in 
observing the lack of significance in the beetroot juice treatment group. 
One limitation was that blood pressure in this study was only measured one time at 
the three measurement points.  In addition, while all measurements for each subject were 
done by the same investigator, the use of a manual blood pressure cuff could have resulted in 
a larger source of variability than using an automatic device.  Previous studies have reported 
reductions in systemic blood pressure due to the beetroot juice treatment even though results 
varied (Bailey et al., 2009; Kapil et al., 2010; Lansley et al., 2011; Vanhatalo et al., 2010; 
Webb et al., 2008).  Both Kapil et al. (2010) and Lansley et al. (2011) observed decreases in 
systolic blood pressure but found no significant change in diastolic blood pressure and mean 
arterial pressure after acute (2.5 hours) beetroot juice supplementation.  Bailey et al. (2009) 
observed similar pressure results to Kapil et al. (2010) and Lansley et al. (2011) after 
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ingestion each day following a chronic (4-6 days) supplementation pattern with beetroot juice 
compared to placebo.  Vanhatalo et al. (2010) observed decreases in systolic blood pressure, 
diastolic blood pressure, and mean arterial pressure after acute (2.5 hours) beetroot juice 
supplementation.  Webb et al. (2008) observed similar results to Vanhatalo et al. (2010) and 
reported that the systolic blood pressure decreases were significant after 2.5 hours post 
beetroot juice ingestion, while the diastolic blood pressure and mean arterial pressure 
decreases were not significant until the 3 hour measurement point post-ingestion.  All of the 
previous studies recorded measurements in triplicate or quadruplicate and used an automatic 
sphygmomanometer which may have resulted in lower variability in measurements (Bailey et 
al., 2009; Kapil et al., 2010; Lansley et al., 2011; Vanhatalo et al., 2010; Webb et al., 2008).  
Furthermore, the time of measurement in this study may have been a reason why significance 
was not observed.  While other studies have shown that systemic blood pressure was reduced 
following beetroot juice ingestion, peak plasma nitrite, cGMP levels, and therefore blood 
pressure reduction effects peaked between 2.5-3 hours post beetroot juice ingestion (Kapil et 
al., 2010; Webb et al., 2008).  In this study, blood pressure could have been measured too 
early in hopes of timing the peak effects of the nitrates to occur during the exercise 
performance trial.  The nitrates in red beetroot juice did not reduce systemic blood pressure 
suggesting that systemic vasodilation did not occur in response to beetroot juice 
supplementation in this study. 
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Time trial results. 
Performance.  All subjects completed a 200 kJ time trial following the ingestion of 
each treatment.  The objective of the test was to complete it as quickly as possible.  Total 
time to completion and the times to complete the first, second, third, and fourth quarters of 
the tests were measured.  Time to completion measurements were used to calculate average 
work rate for each quarter of the time trial and for the entire time trial.  The results revealed 
that under the beetroot juice treatment, mean time to completion was significantly slower and 
mean power output was significantly lower in the 0.00-0.25 segment when compared to the 
other treatments.  No other significant differences were observed in time trial performance.  
It was hypothesized that beetroot juice supplementation would result in a decrease in the 
amount of time it took to complete the time trial compared to placebo and control; however, 
no effects of supplementation on exercise performance were observed.  This hypothesis was 
rejected.  The significant difference in the time to completion of the 0.00-0.25 segment was 
primarily due to the poor performance of three subjects.  Two subjects had the beetroot juice 
treatment first and therefore poor pacing could be a result of unfamiliarity with this type of 
cycle ergometer.  The other had the beetroot juice treatment last.  Observed power for the 
time trial performance analysis was low (0.28), but the inconsistent responses in time trial 
performance of the subjects during the beetroot juice trial, suggest no treatment effect was 
present. 
Previous studies of beetroot juice supplementation on aerobic exercise performance 
have yielded mixed results (Bailey et al., 2009; Lansley et al., 2011; Vanhatalo et al., 2010).  
Lansley et al. (2011) reported significant improvements in time trial performance at both a 4 
km and 16.1 km distance (2.8% and 2.7% decrease in completion time, respectively) 
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compared to the placebo treatment.  They also reported significant improvements in mean 
power output of 5% and 6% for the 4 km and 16.1 km time trial, respectively.  This shows 
evidence of beetroot juice improving the performance of an aerobic cycling test ranging from 
approximately 5 to 30 minutes.  The exercise test in this study falls in the middle of that 
range at approximately 15 minutes.  Furthermore, beetroot juice has been shown to improve 
other types of cycling aerobic exercise tests.  Bailey et al. (2009) found a significant increase 
in time to task failure during a severe intensity constant work rate cycling test to exhaustion 
after 6 days of beetroot juice supplementation that was not observed under the placebo 
treatment.  Additionally, Vanhatalo et al. (2010) found that after more than 5 days of beetroot 
juice supplementation, time to exhaustion and therefore, peak power output, in an 
incremental to maximum exercise cycling test was improved during the test on the 15th day 
of supplementation, but Vanhatalo et al. (2010) did not observe an improvement in time to 
exhaustion after acute beetroot juice supplementation (2.5 hours) or after 5 days of chronic 
beetroot juice supplementation.  All of these previous studies tested beetroot juice 
supplementation under normoxic conditions. 
The nitrates in beetroot juice have been shown to improve cycling performance in 
normoxia (Bailey et al., 2009; Lansley et al., 2011; Vanhatalo et al., 2010), and to have blood 
pressure reduction (Bailey et al., 2009; Kapil et al., 2010; Lansley et al., 2011; Vanhatalo et 
al., 2010; Webb et al., 2008) and vasodilatory effects in the systemic circulation (Kapil et al., 
2010; Webb et al., 2008).  These systemic pressure and vasodilatory effects are stimulated 
through a pathway in which the nitrates get converted first into nitrite and then into nitric 
oxide ultimately affecting cGMP signaling (Kapil et al., 2010; Webb et al., 2008).  Hypoxic 
conditions induce reflexive pulmonary vasoconstriction which impairs aerobic exercise 
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performance (Hahn & Gore, 2001; Hsu et al., 2006; Martin et al., 2010; Richalet et al., 2005; 
Scherrer et al., 1996; Schoene, 2001; Sheel et al., 2010).  While infused nitrite and inhaled 
nitric oxide have been shown to cause pulmonary vasodilation under hypoxic conditions at 
rest (Ingram et al., 2010; Scherrer et al., 1996), dietary nitrates, such as red beetroot juice, 
have not been tested for pulmonary vasodilatory effects.  Hypoxic aerobic exercise 
performance has also not been analyzed under beetroot juice supplementation.  This study 
was designed to monitor indirect indicators of pulmonary vasculature tone and ultimately test 
aerobic exercise performance during beetroot juice supplementation under hypoxic 
conditions. 
Supplementation of pulmonary vasodilators, phosphodiesterase-5 (PDE-5) inhibitors 
have been shown to improve aerobic cycling performance in hypoxic environments (Bailey 
et al., 2009; Ghofrani et al., 2004; Hsu et al., 2006; Richalet et al., 2005).  PDE-5 inhibitors 
have been shown to stimulate these pulmonary vasodilatory effects via cGMP signaling 
(Richalet et al., 2005; Zuckerbraun et al., 2011).  In a study with similar acute hypoxic gas 
exposure (12.8% oxygen) to this current study (~13% oxygen), Hsu et al. (2006) reported an 
increase in a 6 km time trial performance immediately following 30 minutes of cycling at a 
constant work rate of 55% peak power output with the use of PDE-5 supplementation 
compared to placebo supplementation; however, supplementation did not improve 
performance under sea level conditions (Hsu et al., 2006).  Additionally, Richalet et al. 
(2005) reported increased performance on an incremental to maximum cycling test when 
tested on days 2 and 5 of an actual ascent to a similar altitude simulated in this study of 4350 
m.  Likewise, Ghofrani et al. (2004) observed increased exercise tolerance during an 
incremental to maximum cycling test with PDE-5 inhibitor supplementation under both acute 
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hypoxic exposure (of a gas containing 10% oxygen) and chronic hypoxic exposure (after 6 
days of acclimitization at 5,245 m) compared to placebo.  There is a possibility that the 
nitrates in red beetroot juice may have a different mechanism of performance improvement 
than PDE-5 inhibitors and may or may not be effective with pulmonary vasoconstriction or 
aerobic exercise in hypoxia.  In conclusion, the nitrates in red beetroot juice did not improve 
aerobic cycling performance at hypoxia by decreasing time trial time and improving work 
rate in this study. 
 
Physiology.  It was hypothesized that beetroot juice supplementation would result in 
increased arterial blood oxygen saturation levels during the time trial compared to placebo 
and control.  Based on the results from this study, acute beetroot juice supplementation did 
not have an effect on arterial blood oxygen saturation at any completion point throughout the 
time trial when compared to the placebo and control treatments.  This hypothesis was 
rejected.  The only significant effect on arterial blood oxygen saturation observed was due to 
the measurement point during the time trial.  Blood oxygen saturation was significantly 
higher at the starting point of the time trial than at all other completion points of the time trial 
for each treatment.  This was expected since blood oxygen saturation decreases with exercise 
as increasing amounts of oxygen are offloaded from the blood to support the increasing 
metabolic demands of the tissues especially seen during exercise at hypoxia (Banchero et al., 
1966; Bender et al., 1989).  Oxygen saturation remained relatively stable for the duration of 
the time trial in all treatments with the exception of the placebo treatment which showed a 
small but significant drop at the 1.00 completion point compared to the 0.25 completion 
point.  Overall, exercise blood oxygen saturation values under each treatment at a simulated 
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altitude of 4300 m in this study were similar to the 72.7 % mean blood oxygen saturation 
value Bender et al. (1989) reported from averaging blood oxygen saturation values at 5, 15, 
and 30 minutes during a constant cycling aerobic exercise test at 79% VO2max after residing 
at 4300m, Pike’s Peak (460 Torr Barometric Pressure) for 2 days.   
This was the first study to our knowledge that measured blood oxygen saturation 
during beetroot juice supplementation and hypoxic aerobic exercise.  Pulmonary vasodilatory 
(PDE-5 inhibitor) supplementation has been shown to increase arterial blood oxygen 
saturation during aerobic cycling exercise under acute (less than 2 hours) and chronic (days) 
hypoxic exposure (Ghofrani et al., 2004; Hsu et al., 2006; Ricart et al., 2005; Richalet et al., 
2005).  Infused and nebulized nitrite and inhaled nitric oxide have been shown to have 
pulmonary vasodilatory effects under hypoxic conditions in both animal and human tissue at 
rest (Ingram et al., 2010; Scherrer et al., 1996; Zuckerbraun et al., 2010).  It has been shown 
in previous studies that dietary nitrates such as red beetroot juice get converted into nitrites 
and then to nitric oxide, ultimately reducing systemic blood pressure and causing systemic 
vasodilation (Bailey et al., 2009; Kapil et al., 2010; Lansley et al., 2011; Vanhatalo et al., 
2010; Webb et al., 2008).  Vascular tone and pressure has not been measured in the 
pulmonary system during previous beetroot supplementation studies.  Furthermore, the 
effects of beetroot juice supplementation on the pulmonary vascular system have not been 
examined under hypoxic exposure.  Pulmonary vasodilation has been linked to increases in 
blood oxygen saturation and blood flow (stroke volume, ejection fraction, cardiac output) 
(Ghofrani et al., 2004; Hsu et al., 2006; Ricart et al., 2005; Richalet et al., 2005).  Therefore 
increases in blood oxygen saturation and blood flow could suggest the presence of 
pulmonary vasodilation.  Since pulmonary vasculature tone and blood flow could not be 
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measured in this study, arterial blood oxygen saturation was our only method that could 
suggest the state of pulmonary vascular tone.  In this study, beetroot juice had no significant 
effect on blood oxygen saturation levels; therefore, beetroot juice may be improving 
performance at normoxia (seen in previous studies) only through mechanisms other than 
pulmonary vasodilation.  In conclusion, the nitrates in red beetroot juice did not improve the 
arterial blood oxygen desaturation seen during aerobic exercise under hypoxic conditions in 
this study which makes no suggestion of the presence of pulmonary vasodilation. 
Acute beetroot juice supplementation did not have an effect on average oxygen 
consumption (VO2) during the time trial when compared to the placebo and control 
treatments in the current study.  Additionally, there was also no observed correlation between 
average oxygen consumption and time trial completion time.  Lansley et al. (2011) observed 
no differences in average VO2 throughout each time trial between beetroot juice 
supplementation and placebo supplementation for both 4 km and 16.1 km time trials under 
normoxic conditions.  Furthermore, both Bailey et al. (2009) and Vanhatalo et al. (2010) 
observed a decrease in pulmonary VO2, reduced oxygen cost, during submaximal, moderate 
constant work rate cycling exercise after both acute (2.5 hours) and chronic (days) beetroot 
juice supplementation that was not present in placebo.  Bailey et al. (2009) discovered 
significantly increased blood flow and reduced muscle fractional oxygen extraction (supply : 
utilization) with beetroot juice supplementation during a moderate intensity constant work 
rate test suggesting that muscle energy production became more efficient since oxygen 
consumption decreased during a moderate constant work rate bout.  Bailey et al. (2009) 
reported a change in oxygen kinetics (the oxygen uptake slow component was reduced) after 
chronic beetroot juice supplementation (6 days) during the severe intensity constant work 
 
82 
 
rate test to exhaustion without an alteration in fractional oxygen extraction like that seen in 
the moderate intensity constant work rate test.  The continued increase in oxygen 
consumption seen with heavy to severe constant work rate exercise was reduced so that it 
took longer to reach maximum oxygen consumption and exhaustion under beetroot juice 
supplementation compared to placebo (Bailey et al., 2009).  Vanhatalo et al. (2010) observed 
no changes in overall oxygen consumption under beetroot juice supplementation compared to 
placebo for a ramp incremental to exhaustion cycling test after chronic supplementation. 
Furthermore, in the current study, acute beetroot juice supplementation did not have 
an effect on mean cycling economy during the time trial when compared to the placebo and 
control treatments.  This is in contrast to Lansley et al. (2011) whom observed significant 
increases in mean cycling economy, defined as mean power output / oxygen consumption 
(W/L/min), for both the 4 km and 16.1 km time trials (11% and 7%, respectively).  Both 
Bailey et al. (2009) and Vanhatalo et al. (2010) observed a decrease in the functional gain 
ratio (oxygen consumed per minute/power output (ml*min-1/W)) in the moderate intensity 
constant work rate cycling tests.  Furthermore, Bailey et al. (2009) observed a significant 
reduction in the overall gain ratio during the severe intensity constant work rate to exhaustion 
test following 6 days of beetroot juice supplementation compared to placebo.  Like the 
Lansley et al. (2011) study, this also suggests beetroot juice helps improve cycling economy; 
however, Vanhatalo et al. (2010) observed that the functional gain ratio was not reduced in 
the ramp incremental to exhaustion cycling test until 15 days of beetroot juice 
supplementation.  All of the previous exercise tests where completed under normoxic 
conditions.  This is the first time, to our knowledge, that the effect of beetroot juice 
supplementation on oxygen consumption and cycling economy has been examined during 
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hypoxic aerobic exercise.  In conclusion, acute beetroot juice supplementation did not have 
an effect on oxygen consumption and did not improve cycling economy in this study. 
 
Limitations.  Longer hypoxic exposure (a few days) would have more closely 
simulated the physiological hypoxic response to that of an actual race where the athlete 
ascends to an altitude of 4300m a few days before the competition, but we did not have the 
resources (time, money, location, or subject availability) to carry out this protocol.  
Furthermore, arterial blood oxygen saturation can only suggest the presence of pulmonary 
vasodilation.  Due to the expense of a Doppler echocardiography instrument and the 
invasiveness of catheterization, we were not able to use these methods to gain a more 
accurate picture of the pulmonary vasculature.  Also, subject compliance was a possible 
source of variation and error of true results.  Even though subjects were instructed to 
maintain consistent diet, hydration, sleep, and physical activity behaviors and follow the diet 
and physical activity guidelines throughout the study, there was variability in these 
components.  Based on the 24 hour logs, the subjects were compliant with the diet, hydration, 
and sleep requirements.  About half of the subjects were compliant with the physical activity 
restrictions while the other half of the subjects were inconsistent with the intensity, duration, 
mode, and or pattern of outside physical activity performed throughout the study.  This 
variability could have affected performance, but after examination of this specific data, it was 
determined that the data moved in no direction that suggested an effect of compliance on 
exercise performance.  Additionally, even though the observed power was low, possibly due 
to a small sample size and larger variability in responses, there were no consistent changes in 
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performance, and this suggested that beetroot juice supplementation was not effective in 
improving oxygen saturation and performance under the parameters of the study. 
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Conclusion and Direction for Further Research 
Overall, this dose of acute beetroot juice supplementation did not have an effect on 
systemic blood pressure, exercising arterial blood oxygen saturation, and cycling time trial 
performance during the level of hypoxic exposure of this study.  Therefore, dietary nitrate 
supplementation in the form of red beetroot juice may not be a prospective aid for not only 
helping athletes perform better at high altitude events, but also for helping military personnel 
and workers function better during aerobic exercise bout requirements of their job.  Also, 
beetroot juice may not be a prospective aid to help people with pulmonary hypertension, 
pulmonary edema, and hypoxia related diseases function better during everyday activities.  
More testing is needed to more accurately and fully understand the pulmonary vasodilatory 
and performance enhancement potential of red beetroot juice supplementation during aerobic 
exercise at hypoxia. 
This was the first time exercising blood oxygen saturation and aerobic exercise 
performance was analyzed during beetroot supplementation at hypoxia, so further replication 
of the study is needed to validate these results.  Additionally, further studies should 
investigate the effects of different dosages of red beetroot juice supplementation and different 
levels of hypoxia to determine if the dose of beetroot juice in relation to the level of hypoxia 
used in this study was a reason for observing the lack of significance.  Also, further 
investigation could be done to examine the effects in other populations with different 
exercise modality demands, training statuses, and sex than the subjects in this study such as 
military personnel, elite athletes, and female athletes, respectively.  Furthermore, use of a 
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Doppler echocardiography instrument would help to give a more conclusive idea of the 
pulmonary vascular tone under each treatment in response to hypoxia than solely relying on 
the use of arterial blood oxygen saturation levels during exercise which can only suggest the 
presence of pulmonary vasodilation.  Also, actually testing at 4300 m, following an ascent of 
no more than a few days, or residing in a hypobaric chamber for a few days, would allow for 
a more accurate and applicable determination of potential aerobic exercise performance 
effects for those athletes that just go up to altitude for the race only. 
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Request for Review of Human Participant Research 
Appalachian Human Research Protection Program   
IRB #               (12-0255) 
 
Instructions: Complete and send the request form electronically to irb@appstate.edu.   
Note: checkboxes can be checked by putting an “x” in the box. 
 
 
Section I: Study Description  
 
1. Study Title: Effect of acute dietary nitrate supplementation on arterial blood oxygen 
saturation and time trial performance during acute hypoxic exposure in male cyclists and 
triathletes 
 
2. Study Description:  Please describe briefly the objectives of the study with the purpose, 
research question and any relevant background information.  
 
Aerobic performance is impaired at high altitude due to reduced oxygen available to 
the body (aka hypoxia) caused by the reduced partial pressure of inspired oxygen (PIO2) and 
hypoxia-induced pulmonary vasoconstriction.  Hypoxic pulmonary vasoconstriction is a 
reflex mechanism whereby blood vessels in the lung constrict in response to hypoxia.  This 
response reduces the oxygen transfer from the lung to the blood and results in lower oxygen 
delivery to the working muscle.  Supplying vasodilators such as PDE-5 inhibitors has been 
shown to decrease hypoxic pulmonary vasoconstriction and improve blood oxygen levels 
and exercise performance in high altitude environments.  Dietary nitrate supplementation 
has been shown to enhance vasodilation in the peripheral tissues such as exercising skeletal 
muscle, but their ability to alleviate hypoxic pulmonary vasoconstriction and improve 
exercise performance in hypoxia has not been evaluated.  Therefore, the purpose of this 
study is to determine the effect of acute consumption of nitrate-rich red beetroot juice on 
arterial blood oxygen saturation and acute aerobic (approximately 200 kJ) time trial 
performance during acute hypoxic exposure (simulated high altitude (4300 m)) in male club 
level cyclists and triathletes.   
 
3. Principal Investigator(s) and responsible faculty member if student is the PI: PI: 
Jennifer Arms, Faculty Co-Principle Investigator: Dr. David Morris 
Department(s): Health, Leisure, and Exercise Science 
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4. By submitting this request, the Principal Investigator (and responsible faculty member if 
PI is a student) accepts responsibility for ensuring that all members of the research team:  
1) complete the required CITI training and any other necessary training to fulfill their 
study responsibilities, 2) follow the study procedures as described in the IRB approved 
application and comply with Appalachian’s Guidelines for the Review of Research 
Involving Human Subjects and all IRB communication and 3) uphold the rights and 
welfare of all study participants. 
 
The parties (i.e., the IRB and the Principal Investigator and responsible faculty member if 
PI is a student) have agreed to conduct this application process by electronic means, and 
this application is signed electronically by the Principal Investigator and by the 
responsible faculty member if a student is the PI. 
 
My name and email address together constitute the symbol and/or process I have adopted 
with the intent to sign this application, and my name and email address, set out below, 
thus constitute my electronic signature to this application. 
 
 
 Jennifer Arms                                                            armsjc@appstate.edu 
   PI Name             PI Email address 
 
 
__David Morris___                                  morrisdm@appstate.edu      
   Responsible Faculty Name if PI is a student   Responsible Faculty Email address if 
PI is a student 
 
5. Do you plan to publish or present off-campus?   No   X Yes 
6. Does this research involve any out-of-country 
travel? 
X No  Yes 
 
7. Type of Research, 
check all that apply: 
 Faculty Research       X Dissertation/Thesis/Honor’s  
Thesis         
 Product of Learning     Class Project – Course Number:  
 Educational Research Involving Normal Education Practices 
 Other: describe       
 
8. Source of 
Funding 
 Not Funded  Funds Awarded X Funds Pending       
  Federally 
Funded   
 University Funded: describe       
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If funds awarded/pending, provide sponsor name, Sponsored Programs number:  Office 
of Student Research Grant, GSAS Research Grant, Cratis D. Williams Research Grant, 
NSCA GNC Nutritional Grant, NSCA Master’s Grant.       
Attach a copy of the contract/grant/agreement. 
 
9.  Is another institution engaged in the research (i.e., an agent of another institution will 
obtain informed consent, interact with participants to obtain information, or access private 
identifiable information about participants)?    
 X No  Yes If yes, list institution(s) and whether that IRB will review or rely 
 on the ASU IRB.        
 
10.  What, if any, relationship exists between the researcher(s) and agencies (e.g., schools, 
hospitals, homes) involved in the research?  Attach statement of approval (e.g., letter of 
agreement) from any agencies that will be involved with the research. None 
 
 
Section II: Research Personnel 
 
Enter each team member (including PI) in the table below. (A member of the research 
team is defined as one who will: 1) access participants’ private identifiable information, 
2) obtain informed consent or 3) interact with participants.)  
 
Name Role (e.g., PI, 
co-I, Research 
Assistant, 
Research 
Coord., 
Faculty 
Advisor, etc.) 
Responsibilities: 
Select all that apply 
from the list of 
Responsibilities below  
(e.g., “a, b, c”) 
Receive IRB 
Correspondence  
(Y/N)? 
If yes, provide preferred 
email address. 
Jennifer Arms PI a, b, c, e, f, g, j, l, m Yes 
armsjc@appstate.edu 
David Morris Co-PI a, b, c, e, f, g, j, l, m Yes 
morrisdm@appstate.edu 
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(Note: If you need additional room, you can add rows by going to right click, insert, and then 
insert rows below.  Personnel changes made after IRB approval can be submitted via email 
with the above information.) 
Responsibilities:  
a. Screens potential participants h. Conducts physical exams 
b. Obtains Informed Consent i.  Collects biological specimens (e.g., 
blood samples)  
c. Has access to identifiable data j.  Conducts study procedures 
d. Administers survey k.  Dispenses medications 
e. Conducts interviews l.  Supervises exercise 
f.  Enters subject data into research 
records 
m. Educates participants, families, or staff 
g. Analyzes data with identifiable 
information 
n. Other: describe 
Note: In some cases, expertise to perform study procedures (e.g., blood draws, interviewing 
participants about sensitive topics) should be documented by the IRB to show that risks to 
participants is minimized.  The IRB uses the Research Personnel Form to document 
investigator expertise.   
 
Section III: Conflict of Interest 
 
1.  Are there any known or potential conflicts of interest related to this research?   
Conflict of interest relates to situations in which financial or other personal 
considerations may compromise or involve the potential/have the appearance for 
compromising an employee’s objectivity in meeting University responsibilities 
including research activities.   
 
Examples of conflicts of interest include but are not limited to: an investigator has 
equity in a business that conducts research in a related area; an investigator will 
receive an incentive/bonus based on the number or speed of enrollment or outcome of 
a study; or an investigator or family member is a consultant, holds an executive 
position or serves as a board member of the research sponsor or its holdings.  
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 If yes, describe and explain how participants will be protected from the 
influence of competing interests.  
 
Section IV:  Participant Population and Recruitment 
 
1.  Number of participants sought: 12 
 
2.  Targeted Participant Population (check all that apply):  
X Adults (>= 18 yrs old) X College Students (only 18 or older) 
 Minors (< 18 yrs old) Age range:   College Students (under 18 may 
participate) 
 Minorities  Prisoners 
 Institutionalized Participants  Cognitively or emotionally impaired   
 Inpatient participants  Non-English speaking 
 Outpatient participants  Pregnant Participants 
 International research   Employees of a profit or non-profit 
organization 
        
3.  Federal regulations have established guidelines for the equitable selection of participants.  
Are participants an appropriate group to bear the burdens of this research? 
X Yes  No   If no, please explain:  
 
Are participants a subset of the population most likely to receive the benefits of this 
research? 
X Yes  No   If no, please explain:  
 
 
 
 
X No  Yes   
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4.  Explain any inclusion and exclusion criteria for the study:   
 
Inclusion: English speaking male cyclists and triathletes 18-30 years old with at least one 
year of competitive experience and currently training at least three times a week for the past 
eight weeks.  The rationale behind using trained athletes is to standardize the physiological 
response to hypoxia since trained athletes are more impaired than untrained.  Also, by using 
trained athletes, the familiarization effect on the exercise challenges can be limited.  
Additionally, nitrate processing is effected by age; therefore, by limiting the age range to 18-
30 of the exercise challenge, the variance and reduction seen with older age can be 
minimized.  Athletes must have lived at an elevation of 4000 ft (1300 m) or below for six 
months with occasional travel to higher altitudes to standardize the adaptations to altitude.   
 
Exclusion: Females will be excluded since nitrate processing may be influenced by hormones 
which can vary with menstruation cycles.  Participants will undergo aerobic exercise tests; 
therefore, participants that smoke, have a history of pulmonary hypertension, high altitude 
pulmonary edema, cardiovascular disease, cardiopulmonary disease, or physical limitations 
or injuries will not be allowed to participate.  In addition, subjects must not be using 
supplements or other medications such as aspirin, ibuprofen, and acetaminophen that affect 
vascular measures. 
 
5.  Recruitment Procedures (how will you find participants?) 
  Student Subject Pool; indicate pool:  Appalachian State University Club cycling team 
and local cycling and triathlete clubs 
  Email/Mailing/Handout   
 X Website ad/Newspaper ads/Flyers/Postings   
  School children with request sent to parents   
 X Participants will be approached by staff members 
 X Other (explained below) 
 
A copy of any recruitment materials must be submitted with this application. 
 
6.  Explain details of recruitment (e.g., obtain list of student emails from Registrar’s office 
and send them recruitment email): Participants will be approached by staff members at 
meetings such as club cycling meetings.  Subjects will be recruited by word of mouth from 
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the ASU cycling team and local cycling community.  Flyers will be posted around fitness 
facilities. 
 
7.  Does the research include any compensation, monetary inducements, or reimbursement 
for participation in this research study?    
 
 
 
 
Section V:  Informed Consent Process  
 
1.  Explain how informed consent will be obtained. If applicable, include information about: 
the setting, whether participants will have an opportunity to ask questions, and the roles of 
any non-research personnel involved.  If potential participants or their legally authorized 
representatives (e.g., parents) are non-English speaking, please explain how the investigator 
will identify these participants and ensure their ability to understand information about the 
study to provide consent.   
 
Subjects will be required to read and sign an informed consent form.  This will be obtained 
in a laboratory setting.  Only English speaking participants between 18 and 30 years old will 
be used.  Investigators will be present to describe the study and answer questions.  Additional 
screening processes will be used to ensure participants fit the criteria in section 4.4.  A 
medical history questionnaire, along with diet log and training history will be used.  Because 
of these requirements, only English speaking/reading participants will be permitted into the 
study.  All participants will be legally considered adults and will be of sound mind so they 
can enter into the contractual agreement without the necessity of a guardian.  Participants 
will be allowed to ask questions at any time. 
 
7. If applicable, describe the safeguards in place to protect the rights and welfare of any 
vulnerable participants (e.g., children, prisoners, pregnant persons, or any population 
that may be relatively or absolutely incapable of protecting their interests through the 
informed consent process).  
 
 No children, prisoners, or pregnant persons will be recruited.  Furthermore, participant’s 
information will not be made available to anyone except the primary and co-investigators.  
 No X Yes   If yes, explain payment schedule:  All subjects will 
receive $50.00 upon successful completion of all study requirements. 
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All information will be under lock and key.  Once entered into the study, subjects will be 
issued a reference number which will be used to blind all personnel except the investigators. 
 
 
3.  Select factors that might interfere with informed consent:  
X None known 
 Research will involve current students in a course/program taught by member of 
research team 
 Participants are employees whose supervisor is recruiting/requiring participation 
 Participants have a close relationship to research team  
 Other (please specify/indicate any relationship that exists between research team and 
participants):       
 
 
For selected factors, describe any efforts to mitigate:       
 
4.  Will participants sign a consent form? 
X Yes  No 
 
If no, participants must still be provided with a statement regarding the research and one 
of the following criteria must be met and selected and followed:  
 
The only record linking the participant and the research is the consent document 
and the principal risk is potential harm resulting from a breach of confidentiality, and 
the research is not FDA-regulated.  Each participant will be asked whether he/she 
wants documentation linking the participant with the research and the participants 
wishes will govern; OR 
The research presents no more than minimal risk of harm and involves no procedures 
for which written consent is normally required outside of the research context.  
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5.  Are you requesting a modification to the required elements for informed consent for 
participants or legally authorized representatives?  
X No  Yes     If yes, address criteria to waive elements of consent:        
 
 
Section VI:  Study Procedures 
 
1.  Projected data collection dates: Fall 2012- Early Spring 2013 
 
2.  Describe research procedures as they relate to the use of human participants.  Information 
should include what participants will be asked to do, duration of procedures, and frequency 
of procedures.  
 
Following procurement of informed consent, subjects will complete a health history 
questionnaire and an ACSM/AHA Screening Questionnaire designed to prescreen subjects 
for cardiovascular, respiratory, and metabolic disease.  Blood pressure then will be assessed 
using an arm cuff and stethoscope.  Participants will not be allowed to use aspirin, ibuprofen, 
or compounds containing acetaminophen during the study.  No subjects will have previously 
used or will be currently using dietary supplements in the past month for fat soluble 
supplements or past  week for water soluble supplements. If subjects are found fit to 
participate, they will come to the laboratory on 3 separate occasions each separated by one 
week starting one week from the initial visit to perform 3 performance exercise tests.  Each 
visit will be on the same day of the week and same time of day.  During this same initial visit 
a training history will be completed to examine past training status and current training 
intensity, volume, and level of competition.  Height and weight of each subject will be 
measured before he begins the exercise tests. 
 
On the same day as the screening, participants will perform both a VO2 maximum test to 
exhaustion and a practice time trial of the performance test (~ 200 kJ practice time trial) 
under a protocol used in a previous study (Morris et al., 2011).  All tests and the practice trial 
will be performed using an electronically braked cycle ergometer (Lode Excalibur Sport 
Cycle Ergometer, Groningen, Holland) adjusted to the dimensions of the subjects own 
bicycle, while breathing the hypoxic gas.  Following a standardized warm-up, subjects will 
rest for five minutes while equipment is prepared for the graded exercise test.  During the 
test, each stage will be one minute long (Morris et al., 2011).  The power output for the first 
stage will be set at: W=3* mass (kg), and each subsequent stage will increase by 0.3 W * 
mass (kg) (Morris et al., 2011).  Expired respiratory gases will be collected continuously, and 
the gas concentrations will be analyzed by the metabolic cart (Parvomedics Truemax 2400, 
Consentius Technologies, Sandy, UT).  Oxygen consumption, respiratory exchange ratio 
(RER), and heart rate will be monitored in minute intervals throughout the test.  Maximum 
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oxygen consumption (VO2 max) will be determined based on these variables.  Subjects will 
be allowed to cool down with a comfortable load specified by the subject and to walk around 
while the equipment is prepared for the practice trial.  
 
A warm up will not be necessary before this practice performance trial.  The practice 
performance trial will be completed breathing hypoxic gas.  The Lode cycle ergometer will 
be set up to allow manual work rate changes.  Subjects will be encouraged to complete the 
trial as fast as they can.  The total work for the time trial will be based on each subject’s 
body; 3 kJ / kg of body mass.  The only feedback that the cyclist will receive is the work 
performed displayed by the Lode ergometer.  After completion of the prescribed work load, 
subjects will be allowed to cool down with a comfortable load specified by the subject. 
 
The guidelines of participation will be explained in the informed consent.  All subjects will 
be requested to maintain a consistent diet, training program, and physical activity schedule 
throughout the experiment.  In addition, they will be instructed to consume similar meals and 
perform a similar degree of physical activity the day before and the day of the race for all 
three experimental trials.  They will be provided a list of foods which they will be required to 
avoid consuming high levels of nitrates and antioxidants.  Subjects will be asked to abstain 
from caffeine and alcohol twenty-four hours, prior to each performance test.  They will be 
required to keep a log of all fluids and food consumed along with all physical activity 
performed and quality and quantity of sleep obtained twenty-four hours before each visit.  
They will be instructed to avoid strenuous physical activity (no more than thirty minutes of 
greater than or equal to 60% maximum heart rate) twenty-four hours before each 
performance trial.  Participants will be told to drink one liter of fluids the night before and 
one liter of fluids the morning of each visit.  Subjects will undergo a four hour fast in which 
they will only be allowed to consume water before arriving at the lab.  They will be provided 
with the same high complex carbohydrate, low fat and fiber snack, such as a Cliff bar, to eat 
two hours before they arrive at the lab.  Once at the lab, they will not be allowed to eat or 
drink (other than the treatment fluid) three hours before the performance trial.  Furthermore, 
they will not be allowed to drink or consume any fluids or food after the treatment is ingested 
until after the performance test is complete.  Subjects will be asked to abstain from caffeine 
and alcohol twenty-four hours prior to each race.  Finally, subjects will not be allowed to use 
chewing gum or anti-bacterial mouthwash while involved in the study since these are known 
to destroy the oral bacteria necessary for the conversion of nitrate to nitrite (Govoni et al., 
2008).   
 
Participants will arrive at the Vascular, Biological, and Autonomic Studies Laboratory at 
Appalachian State University, room 186C, University Hall, three hours before each 
performance test and will be asked to sit down and rest quietly for fifteen minutes.  Fifteen 
minutes after arrival, systemic blood pressure will be measured using an arm stethoscope and 
cuff.  Thirty minutes after arrival, subjects will be required to drink the treatment.  The 
supplemental fluid will contain either 91 ml of organic beetroot juice (BR) (containing ~5.77 
mMol of nitrate; Beet it, James White Drinks Ltd., Ipswich, UK), 91 ml of organic nitrate 
depleted beetroot juice (PL) similar to the beetroot juice in color, taste, texture, and odor 
(containing ~0.048 mMol of nitrate; Beet it, James White Drinks Ltd., Ipswich, UK) 
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(Lansley et al. (2011)), or 91 ml of water (CO).  The treatment will be assigned and 
administered in a randomized double blind design.   
 
Two hours and forty-five minutes after arrival, resting systemic blood pressure will be 
measured.  A standardized 10 minute warm-up will be performed under hypoxic conditions 
prior to commencement of each performance test.  Immediately following the warm-up, 
another systemic blood pressure measurement will be taken.  Subjects will then rest for five 
minutes while the equipment is prepared for the performance test.  The Lode ergometer will 
be placed in time trial mode to allow for adjustment of work rates.  Fifteen minutes past the 
warm-up start time, subjects begin the performance test.  Subjects will be able to change 
work rates as desired throughout the test with the objective of completing the prescribed 
work load as fast as possible.  As in the practice trial, cyclists will receive feedback only on 
their work completed and will be blinded to elapsed time and power output.  The 
investigators will give verbal encouragement similar to that in the pre-supplementation trial.  
VO2 and RER will be monitored with the metabolic cart throughout the performance test.  
Blood oxygen saturation, elapsed time, and heart rate will be recorded at 0.25, 0.50, 0.75, and 
1.00 of the total kilojoules completed.  Blood oxygen saturation and heart rate will be 
measured using a pulse oximeter that will be clipped to the subject’s earlobe.  After 
completion of the trial, subjects will be allowed to remove the mouth piece and nose clip and 
cool down. 
 
During all of the pre-supplementation tests and experimental tests, each subject will be 
exposed to hypoxic gas similar to the set up used in a previous study (Morris et al., 2000).  
The device used was designed and tested by Dr. Morris.  He has used this device to 
manipulate inspired oxygen concentrations in several research studies and in hundreds of 
training sessions using athletes at the United States Olympic Training Center in Colorado 
Springs, CO and in a previous investigation at Appalachian State University (Study# 11-0065 
Effects of garlic on exercising blood oxygen desaturation and performance in hypoxia).  The 
device consists of a cylinder containing medical grade breathing gas of 6% oxygen 94% 
nitrogen mixture.  This mixture is pumped into meteorological balloon which serves as a 
reservoir.  Leading from the balloon is a breathing tube that is attached to a dual intake valve.  
The dual intake valve has three ports: Two of these ports allow for intake of air with one of 
these ports leading to the atmosphere and the other leading to a gas reservoir containing the 
hypoxic gas.  The third port on the dual intake valve leads to a hose that is attached to the 
inspired port of a standard Hans Rudolph model 2700 breathing valve.  The subject is 
attached to the breathing port of this Hans Rudolph valve.  As the subject inspires, equal 
amounts of air will flow from the gas reservoir and the atmosphere through the dual intake 
valve ports.  The resultant mixture delivered to the subject will have an oxygen concentration 
of ~13% which provides a similar PIO2 to that experienced at an altitude of 14,000 ft.  The 
use of the dual intake valve provides two advantages: 1. Should any part of the hypoxic gas 
reservoir system become plugged, or should the gas cylinder/reservoir become empty while a  
subject is using the device, air delivery will be maintained through the atmospheric port of 
the dual intake valve.  2. Mixing the dry gas mixture from the cylinder with atmospheric air 
humidifies the air and helps prevent the subject from developing a dry mouth and throat 
which can lead to excess mucous production. 
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The total involvement time will be approximately 14 hours over 30 days.  The initial visit 
will last approximately 90 minutes and the final 3 visit will require four hours of time.  Both 
the VO2 max and performance tests will be proceeded by a 10 minute warm-up under 
hypoxic conditions.  Previous research by the author suggests that the VO2 max test will last 
5-7 minutes and the performance trial will take 15-20 minutes under hypoxia... 
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Experimental Trial 
~200 kJ Time Trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3:00 2:45 2:30 0:15 0:00 + 0:10 +0:15 Every ¼ total kilojoule completed                                  3 kJ/ kg bwt 
 
Measure: 
BP 
Measure: 
BP 
Drink 
Treatment:  
0.05L of: 
 
BR, PL, or CO 
Measure: 
Oxygen saturation 
HR 
Time 
Measure: 
Total time 
Cool down 
Treatment Fluids: 
Acute (1 dose) supplementation 
• 91 ml Organic beetroot juice (BR) (~5.77 mMol nitrate) 
• 91 ml Nitrate depleted organic beetroot juice (PL) (~0.048 mMol nitrate) 
• 91 ml water 
*Crossover design: Each subject will experience each treatment. 
-randomly assigned order 
 -each experimental trial separated by 1 week 
 - each trial same day of the week and time of the day 
Arrive at lab 
Rest Quietly 
Measure:  
BP 
Begin: 
Time Trial 
Warm up 
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3. Participants’ identification (check one):   
 Information is collected so that participants CANNOT be identified directly (by 
names, images or other identifiers) or indirectly (by linking responses to participants).  
Information is collected so that participants CAN be identified, either directly or 
indirectly, by the research team but identifying information will not be disclosed 
publicly.         
Information is collected so that participants CAN be identified, either directly or 
indirectly, by the research team and identifying information will be disclosed 
publicly.        
  
4.  Check all locations of study procedures that apply:  
 N/A – online survey 
X Appalachian campus, indicate building: Vascular Biology and Autonomic Studies 
Laboratory, Institute of Health and Human Services, Boone, NC 
 School system(s):       
 Human Performance Lab, NCRC 
 Off-campus location(s).  List:       
 
5.  Data collection 
5a. Please check all data collection activities involved in this study: 
X Paper Surveys / Questionnaires 
 Online Surveys / Questionnaires   Name of Survey Provider:       
 Telephone Surveys / Questionnaires   Name of Survey Provider:       
 Standardized Written / Oral / Visual Tests 
X Interviews 
 Focus Groups 
 Tasks 
 Public Observation 
 Classroom Observation/Work Site Observation 
 
X 
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 Voice, video, digital or image recordings made for research purposes 
 Materials (i.e., data, documents, records/specimens) that have been collected or will 
be collected for non research purposes 
 
X Collection or study of materials (i.e., data, documents, records/specimens) that are 
publicly available or if the information is recorded so that participants cannot be 
identified, directly or indirectly through identifiers  
 Materials (i.e., data, documents, records/specimens) that have been collected for 
another research project 
X Moderate exercise and muscular strength testing   
X Other:  Maximal Exercise 
 
5b. If your study does not involve biomedical procedures skip to question #6. Otherwise, 
select all data collection activities that apply: 
 Blood samples by finger stick, heel stick, ear stick or venipuncture 
Indicate the type of participants and how much blood will be drawn: 
  from healthy, non pregnant adults who weigh at least 110 pounds 
  from other adults or children 
  How many times per week will blood be drawn?       
  How much blood will be drawn at one time?       
  How much blood will be drawn in an 8-week period?       
  How often will collection occur?       
 Noninvasive procedures to collect biological specimens for research purposes 
 Sterile Surgical/Invasive procedures 
 Banking of biological materials 
X Noninvasive procedures to collect data such as use of physical sensors applied 
to surface of body and electrocardiography 
 
 Procedures involving x-rays (e.g., DEXA scan for body composition) 
 
 
 109 
 
 
 
 
 
 
 
 
 
5c. Is this research FDA-regulated (i.e., It is an experiment that involves one or more of 
the following test        articles:  foods/dietary supplements that bear a nutrient 
content/health claim, infant formulas, food/color additives, drugs/medical 
devices/biological products for human use)?    
X No  Yes 
 
6.  Is deception involved?  
   
 
 
 
7.  Does the data to be collected relate to any illegal activities (e.g., immigration status, drug 
use, abuse, assault)?     
 
 
 Ingestion of wholesome foods without additives 
X Ingestion/application of substances other than wholesome foods without 
additives 
 Clinical study of a drug/medical device 
 Obtaining medical data from a health care provider, health plan or health care 
clearinghouse 
 Genetic Testing 
 Other:  
  No X Yes      If yes, please describe: Subjects will be blinded to the 
application of the treatments 
 
 X No  Yes      If yes, please describe:       
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Section VII:  Confidentiality and Safeguards 
 
1.  In most cases, the research plan should include adequate provisions to protect the privacy 
of subjects.  How will the confidentiality of participants be maintained (e.g., how will access 
to participants be controlled)? 
The individual’s file and hardcopy data will be locked in a file cabinet within a locked office 
in a secure building. 
 
2. Will collected data be monitored to ensure the safety of subjects (e.g., survey includes 
a question about suicidality so the investigator will…)?      
 
3. Describe what will be done with the data and resulting analysis: 
 
The data will be coded and entered into a computer spreadsheet and all individual identifiers 
will be removed and replaced with a subject number.  Following that, analysis will be run 
and results will be published in peer-reviewed journals.  All hardcopy data will be destroyed 
and the computer files will be erased (destroyed) 5 years following the protocol.  All data 
will be used only for the purpose of this study and no data will be shared with anyone outside 
the immediate study team. 
 
4.  Describe measures you are taking to safeguard study data (check all that apply): 
X Data is not linked to identifying information       
X Maintain consent forms in a separate location from data       
X Using subject codes on all collected data and maintaining the key linking subject 
codes with  
identifiable information in a separate location from data       
 
  No X Yes      If yes, please explain procedures to ensure safety of participants: Data 
written in reports and manuscripts will not be linked to or identify individual 
subjects.  Subjects will further be protected from being identified by avoiding 
photography and the use of personal names. No harmful use of the data is 
intended.  If any issues arise the PI will be notified and will address each 
situation.  Participants will be regularly asked about their willingness to 
continue their participation along with their compliance to the protocol 
throughout each visit. 
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X Locking cabinets/doors.  List location:       053 Holmes Convocation Center   
X Data kept in area with limited public access. List location:    053 Holmes Convocation 
Center           
X Password protected computers       
 Encryption 
 PDAs and removable media (e.g., CDs, etc.) will be kept in a secure location. List 
location:          
 Other, please describe:            
 
 5. Data Sharing 
5a. What type of data will be shared? (Note: Sharing includes releasing, transmitting and 
providing access to outside of the research team.) Check all that apply: 
 Data collected anonymously 
 Anonymized or De-linked data. Identity was once associated with data/specimen but 
identifying information destroyed 
 
 Coded and linked data (Data is coded.  With the code, the data may be linked back to 
identifiers, but the link back to identifiers will not be shared.)       
 
 Identifiable Data (e.g., names, email addresses, date of birth, IP addresses) 
Indicate which secure method(s) of transmission will be used:         
 
5b. If identifiable data will be shared within or outside of the research team, please 
explain how it will be shared (check all that apply): 
 Secured Website.  Please provide name of website:       
 Encrypted email       
 U.S. Postal Service or other trackable courier services 
 Fax in a secured area 
X Shared drive with password protection 
 Personal delivery by member of research team 
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 Private telephone conversation to member of research team 
 Other, please describe:       
 
6. Secure Disposal:  Note: consent forms should be stored for 3 years after study completion. 
6a. How long will the data be stored?  
 1 year after study conclusion      X 5 years after study conclusion 
 Indefinitely  Data without identifiers stored indefinitely 
 Other, please describe (e.g., sponsor requirements):       
 
6b. How will data be destroyed? 
X Paper will be shredded        Biological samples will be destroyed by:       
X Destroy electronic files from computer/PDAs/removal media (CDs, diskettes) by: 
deletion 
 Other, please describe:       
 
 
Section VIII:  Risk and Benefits of Study 
 
1.  The risks to participants must be reasonable in relation to anticipated benefits, if any, to 
participants and the importance of the knowledge that may be reasonably be expected to 
result.  Select all applicable: 
 Participants of the study may directly benefit by (describe): [Note that compensation 
is not considered a benefit.]  
 
Beetroot juice may help improve aerobic exercise performance at high altitude.  Some 
cycling and triathlete competitions are held at moderate to high altitude where aerobic 
performance is impaired.  All subjects will gain awareness of their performance results and 
physiological responses in relation to simulated high altitude.  They may also gain a better 
understanding of methods to alleviate hypoxia induced pulmonary hypertension and 
improvement of exercise performance in high-altitude environments. 
 
X 
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 Society may benefit from the study by (describe):    
 
This treatment could potentially help athletes improve exercise performance at high 
altitude.  Evidence of this mechanism could be very beneficial to multiple populations.  Not 
only could it help non-acclimatized athletes be more competitive at moderate to high altitude 
events, but it could also help military personnel and other workers who perform duties at 
high altitude or hypoxic environments.  In addition, dietary nitrate induced pulmonary 
vasodilation may be a prospective aid for reducing pulmonary hypertension, hypoxia, and 
pulmonary edema, ultimately improving everyday performance in diseased populations 
(Zuckerbraun et al., 2011).   
 
2.  Describe the potential risks (e.g., psychological, legal, physical, social harm, loss of 
confidentiality) to any individual participating in this project:   
 
Possible side effects for moderate to maximal-intensity cycling include brief feelings of 
nausea, lightheadedness, or dizziness after the completion of the exercise, especially when 
exercise is performed in hypoxia. Exercise testing with gradually increasing workloads to the 
point of fatigue is associated with a very minimal risk of death (0.01%) and complications of 
the heart (0.04%).  Exercise in hypoxia increases the likelihood of lightheadedness and/or 
dizziness.  However, breathing of hypoxic mixtures during rest and exercise is a relatively 
safe procedure that has been in use in research settings for many years.  The gas mixture we 
are proposing simulates an altitude of 14,000 feet.  This level of hypoxia has been studied in 
numerous laboratories in the past without adverse effects.  Additionally, the Maher Research 
Laboratory, located at 14,000 feet on Pike's Peak, routinely studies human subjects during 
rest and heavy exercise without encountering significant adverse effects.  Dr. Morris spent 10 
years working as a physiologist for the United States Olympic Committee and USA Cycling.  
During this period he performed research and oversaw hundreds of training sessions that 
utilized maximal exercise in hypoxia.  While minor symptoms such as dizziness and 
lightheadedness were occasionally observed, severe symptoms such as fainting were never 
observed and he has never had to terminate an exercise test or training session due to adverse 
reactions to hypoxia.  The symptoms that do occur while breathing hypoxic air quickly 
subside when the subject returns to breathing normoxic air.   
This is the same protocol that was approved previously to test garlic supplementation on 
hypoxic aerobic exercise performance. 
 
3. Assessment of level of risk: 
 Risks (including physical, emotional, social, legal or financial) are the same as 
encountered in daily life or during the performance of routine physical or 
psychological examinations or tests (minimal risk). 
Risks are more than minimal in that either: a) the probability of harm or discomfort 
anticipated, or b) the magnitude of harm or discomfort anticipated is greater than that 
X 
X 
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encountered in daily life. 
Information to be collected could cause participants to be at risk of criminal or civil 
liability if responses are disclosed outside of the research setting. 
Information to be collected could be damaging to participant’s financial standing, 
employability, or reputation if disclosed outside of the research setting. 
 
3. Describe procedures for protecting against, or minimizing, the potential risks:   
 
All subjects will be highly trained cyclists with no history of adverse cardiac risk. These risks 
are exceptionally low in this subject group, whose members frequently (several times per 
week) participate in training sessions or competitions having physical demands similar to the 
protocols of the proposed study. Typical weekly training volumes for these types of subjects 
are at least 4-5 hours per week with .5-1 hours per week in excess of 90% of maximal heart 
rate. At least two technicians trained in CPR will be present for all tests. All research team 
members will have previous exercise testing experience and will be aware of the signs and 
symptoms associated with possible adverse reactions during exercise.  To further ensure a 
low risk subject population, each subject will be screened using a Health History 
Questionnaire and the ACSMAHA Screening Questionnaire.  Only subjects that are 
classified as "low risk", ie no more than 1 risk factor for cardiovascular disease, by ACSM 
risk startification rankings will be retained as subjects.  During exercise in hypoxia, subjects 
will be observed closely for significant adverse reactions such as loss of consciousness and 
exercise will be terminated should any of these symptoms be observed.  Blood oxygen 
saturations will be monitored throughout the exercise and recovery periods.  Typical blood 
oxygen saturation during rest at sea-level are 98%-100%.  During maximal exercise these 
levels will drop into the mid 80% range (Rowell et al, 1964).  Numerous investigations have 
executed maximal exercise tests at simulated altitude that are similar to the altitude that we 
are proposing (Cymmerman et al, 1989; Favier et al 1995; Hughson et al, 1995; Stoneham et 
al, 1993) and have observed blood oxygen saturations at maximum exercise averaging in the 
mid 60% to low 70% range with the lowest observed oxygen saturation being 50% during 
maximal exercise at a PIO2 of 88 Torr.  Additionally, Cymmerman et al, 1995, studied 
maximum oxygen consumption in subjects at a simulated altitude of 8800 meters or PIO2 of 
43 Torr (Mt Everest) and observed average blood oxygen saturations of 35% during maximal 
exercise.  None of these investigators observed any serious or long term negative effects to 
hypoxia and, after removal from hypoxia,  blood oxygen saturations typically returned to 
normal within 1 - 2 minutes.  We do not anticipate oxygen saturations below 50% and will 
immediately halt exercise and return to normoxia any subject who exhibits oxygen 
saturations below 45%.  Upon termination of the VO2 max and performance tests, subjects 
will be returned immediately to normoxia and be given 10 minutes of low intensity cycling 
followed by 5 minutes of rest in the seated position.  During these periods, the subject's blood 
oxygen saturations will be monitored continuously for any negative reactions to exercise 
and/or hypoxia.   
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5.  If human subject data/specimens will be used for future research that is not described 
above, please explain.  (Future use of data/specimens should be disclosed to the participant in 
the informed consent.)  N/A 
    
Please check any materials below that will be submitted with your application.  Note: please 
submit as separate files. 
X Recruitment wording 
X Consent form(s) 
 Letter(s) of Agreement 
 Research Personnel Form(s) 
X Instruments (Survey questions, interview questions, etc.) 
 Copy of grant/contract/agreement 
X Other (please describe): Data Forms, Health History Questionnaire, Diet, Physical 
Activity, and Sleep logs, Diet and Exercise instructions 
 
Please send an electronic Word attachment (not scanned) of this application and any 
accompanying materials to irb@appstate.edu. Thank you for taking your time to promote 
ethical human participant research at Appalachian! 
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Consent to Participate in Research 
Information to Consider About this Research 
 
Beetroot Juice Dietary Nitrate Supplementation and Hypoxic Aerobic Exercise 
Performance 
 
Co-Principal Investigator: Dr. David Morris 
Department: HLES 
Contact Information: 
Appalachian State University 
 
53 Holmes Center 
 
111 Rivers St. 
 
Boone, NC 28607 
 
morrisdm@appstate.edu 
 
828-262-7120 
 
Principle Investigator: Jennifer Arms 
armsjc@appstate.edu 
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What is the purpose of this research? 
 
Exposure to high-altitude environments has been shown to reduce blood oxygen levels and 
hinder the circulation of blood through the lungs.  These responses contribute to reductions in 
aerobic exercise performance at high-altitude.  Nitric oxide is a compound that occurs 
naturally in the body and helps to increase blood flow.  Nitric oxide levels can be increased 
by consuming foods that contain high levels of nitrates.  Beetroot juice contains high levels 
of nitrates and its consumption has been shown to increase forearm blood flow and improve 
exercise performance at sea level.  However, the ability of beetroot juice consumption to 
improve blood circulation in the lung, blood oxygen levels, and exercise performance in high 
altitude environments has not been studied.    By doing this research, we hope to learn if a 
small dose of beetroot juice consumed 2.5-3 hours prior to exercise can increase blood 
oxygen levels and cycling time trial performance.   
 
Why am I being invited to take part in this research? 
 
You are being invited to take part in this research because you are a healthy, highly- 
endurance trained, non-smoking male cyclist or triathlete who is accustomed to performing 
high-intensity exercise. 
 
Are there reasons I should not take part in this research? 
 
If you do not conform to the above listed requirements, or if you have any known 
cardiovascular, respiratory (pulmonary hypertension, high altitude pulmonary edema) or 
metabolic diseases, you should not participate in this study.  If you volunteer to take part in 
this study, you will be 1 of about 12 people to do so. 
 
What will I be asked to do? 
 
The research procedures will be conducted at Appalachian State University, Vascular, 
Biological, and Autonomic Studies Lab, RM 186C, University Hall.  You will need to come 
to this location 4 times during the study.  Your initial visit will require about 90 minutes and 
your final 3 visits will each require about 4 hours of your time.  The total amount of time you 
will be asked to volunteer for this study is approximately 14 hours over the next 30 days. 
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During your initial visit, you will be asked to complete a health history questionnaire and the 
American College of Sports Medicine/ American Heart Association screening questionnaire 
designed to prescreen subjects for cardiovascular, respiratory, and metabolic disease.  Blood 
pressure will then be assessed using an arm cuff and stethoscope.  You will also be required 
to fill out a training history.  If you are declared fit to participate, you will then perform a 
progressive, maximal exercise test to exhaustion so that we can determine your VO2 max 
and the work rate that elicits your VO2 max.  VO2 max is a measure of your aerobic fitness.  
It allows us to determine how much oxygen your body can use to provide fuel for your 
working muscle.  Immediately prior to starting the VO2 max test, you will be required to 
perform a 10-minute warm-up at a low to moderate intensity.  Then the max test itself will 
start at a low to moderate level intensity   which will be increased by a small amount each 
minute until you are exhausted.  The maximal test itself generally takes about 6-8 minutes to 
complete.  During the test, a snorkel-like mouthpiece will be placed in your mouth and your 
nose will be plugged with a nose clip. This will allow us to collect your expired air and 
analyze it to determine your oxygen consumption level.  The maximal test will be performed 
under a simulated high-altitude condition.  To achieve this condition, you will be breathing 
medical grade gas with an oxygen concentration that is lower than what is found in the 
atmosphere.  This altered gas mixture will simulate an altitude of approximately 14,000 ft.  
Once you have completed the maximal test, the mouthpiece will be removed and you will be 
able to breathe normal sea level air.  You will then be allowed to recover for approximately 
20 minutes.  Following your recovery, you will be asked to perform a practice trial of an 
exercise test that you will be performing on your subsequent visits.  This practice trial will 
consist of time trial of approximately 12 km in length.  During this trial, you will be able to 
adjust the work rate (intensity) of your exercise at your discretion, but you will be 
encouraged to finish prescribed distance as quickly as possible.  This trial will also be 
performed while breathing the low oxygen gas mixture and will require approximately 20 
minutes to complete.  Once the practice trial is completed, you will be able to cool down on 
the bike breathing normal sea level air.  All of these tests and the tests that are performed on 
subsequent visits will be performed on a bicycle ergometer with dimensions that will match 
your own bicycle. 
 
Following the initial evaluation, you will be asked to return to the lab on 3 occasions, each 
visit will be separated by a week.  You will be placed on the following exercise and diet 
restrictions during your involvement: avoid strenuous exercise and maintain a consistent diet 
on the day prior to each visit, avoid alcohol and caffeine consumption for 24 hours prior to 
each visit, avoid anti-bacterial mouth wash and chewing gum while participating in the study, 
and avoid the foods on the list that will be given to you of high nitrate and antioxidant 
containing foods throughout the study.  You will be required to keep a log of all fluids and 
food consumed as well as all physical activity completed and quality and quantity of sleep 24 
hours prior to each trial. You will be asked to drink at least one liter of fluids the night before 
and morning of the trial.  You will be given a small snack (2 Clif Bars) to be consumed two 
hours before your arrival at the laboratory, but will otherwise be required to avoid consuming 
food (other than water) for 4 hours prior to each visit   Upon arrival at the laboratory, you 
will be seated and will rest quietly for 10-15 minutes, after which blood pressure will be 
taken.  Thirty minutes after arrival, you will be then be given 1 of 3 supplement options:  
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91ml of beetroot juice, 91ml of a placebo juice, or 91ml of water.  You will then be asked to 
sit quietly for 135 minutes.  During this period you will not be allowed to perform physical 
exercise, but you will be allowed to perform sedentary activities such as reading, studying, 
watching videos or listening to music.  We will then take another blood pressure 
measurement with a stethoscope and blood pressure cuff.  You will then begin a 10-minute 
warm-up while breathing the low oxygen gas mixture.  Following the warm-up you will be 
allowed approximately 5 minutes to stretch and use the restroom.  You will then remount the 
bicycle ergometer, begin breathing the low oxygen gas mixture and complete the 12 km time 
trial.   During each time trial you will have a sensor that looks like a small ear clip, clipped to 
your ear lobe to monitor blood oxygen saturation and heart rate.  You will be allowed to 
adjust your work rate during the time trial as you desire, but you will be encouraged to finish 
each trial as quickly as possible.  You will be blinded to your actual work rate, but the 
cumulative distance completed will be constantly updated and displayed by a digital readout. 
Upon completion of the trial, you will take out the mouth piece and take off the nose clip and 
will be allowed to cool down.  
 
 
 
 
123 
Experimental Trial 
~200 kJ Time Trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3:00 2:45 2:30 0:15 0:00 + 0:10 +0:15 Every ¼ total kilojoule completed                        3 kJ/ kg bwt 
 
Measure: 
BP 
Measure: 
BP 
Drink 
Treatment:  
0.05L of: 
 
BR, PL, or CO 
Measure: 
Oxygen saturation 
HR 
Time 
Measure: 
Total time 
Cool down 
Treatment Fluids: 
Acute (1 dose) supplementation 
• 91 ml Organic beetroot juice (BR) (~5.77 mMol nitrate) 
• 91 ml Nitrate depleted organic beetroot juice (PL) (~0.048 mMol nitrate) 
• 91 ml water 
*Crossover design: Each subject will experience each treatment. 
 -randomly assigned order 
 -each experimental trial separated by 1 week 
 - each trial same day of the week and time of the day 
Arrive at lab 
 
Rest Quietly 
Measure:  
BP 
Begin: 
Time Trial 
Warm up 
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What are possible harms or discomforts that I might experience during the research? 
 
We know about the following risks or discomforts that you may experience if you choose to 
volunteer for this study: 
 
Possible side effects for moderate to maximal-intensity cycling include brief feelings of 
nausea, lightheadedness, or dizziness after the completion of the exercise, especially when 
exercise is performed in hypoxia.  Exercise testing with gradually increasing workloads to 
the point of fatigue is associated with a very minimal risk of death (0.01%) and 
complications of the heart (0.04%).  Exercise in hypoxia increases the likelihood of 
lightheadedness and/or dizziness.  However, breathing of hypoxic mixtures during rest and 
exercise is a relatively safe procedure that has been in used in research settings for many 
years.   
 
Nitrate supplementation via beetroot juice consumption has been shown to cause dilation of 
the blood vessels in the forearm.  Therefore, nitrate supplementation may potentially 
decrease blood pressure.  However, nitrate supplementation has not been shown to reduce 
blood pressure to unsafe levels which would produce symptoms such as light headedness, 
dizziness, or feeling faint. 
 
Some research using animal models suggests the body can convert nitrates into substances 
that are potentially harmful.    However, direct evidence of nitrate related cancer from long 
term dietary nitrate consumption is inconclusive and lacking in human studies.   Research 
also suggests that this conversion to carcinogenic compounds from dietary nitrate ingestion 
may not be the favored pathway in children and adult humans.  Not all nitrate sources have 
the same effect and recent evidence suggests that substances found in fruits and vegetables 
such as Vitamin C may reduce the formation of these harmful substances.  It has been shown 
that people who have a high nitrate diet through a high consumption of fruits and vegetables 
have a lower incidence of mortality due to gastric cancer.  The World Health Organization 
has set a daily acceptable intake of 0- 3.7 mg/ day.  Americans typically consume 40-100 mg 
of nitrate per day through their diet with the highest sources of nitrate being celery, lettuce, 
spinach, and beets.  A 2-inch beet that weighs about 82 grams (250 mg of nitrate per 100 
grams) contains about 205 mg of nitrate.  We would be asking you to undergo a short term 
supplementation.  You would consume approximately 357.5 mg one time for the beetroot 
juice treatment (BR) and approximately 0.2 mg of nitrate one time for the placebo 
intervention throughout the entire study. 
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Are there any reasons you might take me out of the research? 
 
If you do not follow the protocol, you will not be allowed to continue to participate in the 
study.  During the study, information about this research may become available that would be 
important to you and may affect your willingness to participate.  This might include 
information about the side effects that are caused by taking part in this study.  If this happens, 
we will tell you about these new side effects and let you decide whether you want to continue 
to take part in the research. 
 
There may be reasons we will need to remove you from the study, even if you wish to 
continue to participate.  We may find out that it is not safe for you to stay in the study.  It 
may be that the side effects from the treatments or hypoxic exercise are so severe that we 
need to stop the study or take you out of the study to reduce your risk of harm.  If we find 
that the research might harm you or that it is not providing enough of a benefit to justify the 
risks you are taking, we will terminate your involvement in the study.  We may also find that 
you are not or cannot take your supplement properly or you are not or cannot come for your 
study visits as scheduled.  If these things are found to be true, we will need to take you out of 
the study. 
 
What are possible benefits of this research? 
 
You will learn your VO2 max and time trial performance results that would be applicable if 
you were competing at high altitude.  This research should help us learn more about dietary 
nitrate supplementation and if it can improve aerobic exercise performance at hypoxia/ high 
altitude.  The information gained by doing this research may help you and others to compete 
in hypoxic/ high altitude environments. 
 
Will I be paid for taking part in the research? 
 
We will pay you $50.00 for the time you volunteer while being in the study.  You must 
complete the entire protocol to receive your payment.    You will need to provide your 
address when you complete the form for payment. 
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How will you keep my private information confidential? 
 
Your information will be combined with information from other people taking part in the 
study.  We intend to publish the results of the study so that it may be shared with other 
researchers.  This publication will only contain the combined information from you and the 
others who participated in the study.  You will not be personally identified in any published 
or presented materials. 
All personal information obtained during the course of your participation will be accessible 
only to Dr. Morris and members of his research team.  You will be identified by code to 
preserve your confidentiality and your file will be kept in a locked cabinet in Dr. Morris’s 
office.  We will make every effort to prevent anyone who is not part of the research team 
from knowing that you gave us information or the content of that information.  However, 
there are some circumstances in which we may have to show your information to other 
people.  For instance, we may be required to show information that identifies you to people 
who need to be sure that we have done the research correctly, such as Appalachian State 
University’s Institutional Review Board.  Data form this research will be kept indefinitely, 
however, codes linking you to your data will be destroyed three years following the 
completion of the data collection. 
 
What if I get sick or hurt while participating in this research study? 
 
If you need emergency care while you are at the research site, it will be provided to you.  If 
you believe you have been hurt or if you get sick because of something that is done during 
the study, you should call your doctor or, if it is an emergency, call 911 for help.  In this case, 
tell the doctors, the hospital or emergency room staff that you are taking part in a research 
study and the name of the Principal Investigator.  If possible, take a copy of this consent form 
with you when you go.  Call the Co-Principal Investigator, David Morris, at 828-262-7120 as 
soon as you can.  He needs to know that you are hurt or ill. 
 
There are procedures in place to help attend to your injuries or provide care for you.  Costs 
associated with this care will be billed in the ordinary manner to you or your insurance 
company.  However, some insurance companies will not pay bills that are related to research 
costs. You should check with your insurance company about this.  Medical costs that result 
from research-related harm may also not qualify for payments through Medicare, or 
Medicaid.  You should talk to the Principal Investigator about this, if you have concerns. 
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Who can I contact if I have a question? 
 
The people conducting this study will be available to answer any questions concerning this 
research, now or in the future.  You may contact the Co-Principal Investigator, David Morris 
at 828-262-7120.  If you have questions about your rights as someone taking part in research, 
contact the Appalachian State University Institution Review Board Administrator at 828-262-
2130 (days), through email at irb@appstate.edu or at Appalachian State University, Office of 
Research and Sponsored Programs, IRB Administrator, Boone, NC 28608. 
 
Do I have to participate?  What else should I know? 
 
Your participation in this research is completely voluntary.  If you choose not to volunteer, 
there will be no penalty and you will not lose any benefits or rights you would normally 
have.  If you decide to take part in the study you still have the right to decide at any time that 
you no longer want to continue.  There will be no penalty and no loss of benefits or rights if 
you decide at any time to stop participating in the study. 
This research project has been approved by the Institutional Review Board (IRB) at 
Appalachian State University.  This study was approved on _6/1/2012___.  This approval 
will expire on _4/18/2013__unless the IRB renews the approval of this research. 
 
I have decided I want to take part in this research.  What should I do now? 
 
The person obtaining informed consent will ask you to read the following and if you agree, 
you should sign this form: 
• I have read (or had read to me) all of the above information. 
• I have had an opportunity to ask questions about things in this research I did not 
understand and have received satisfactory answers. 
• I understand that I can stop taking part in this study at any time. 
• By signing this informed consent form, I am not giving up any of my rights. 
• I have been given a copy of this consent document, and it is mine to keep. 
 
 
Participant’s Name (PRINT)    Signature   
 Date 
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ASU/NCRC SCREENING QUESTIONNAIRE* 
 
ID NUMBER      _________________________________________________ 
Assess your health status by marking all true statements 
 
MEDICAL HISTORY  
_____ a heart attack                                   
_____ heart surgery  
_____ cardiac catheterization  
_____ coronary angioplasty (PTCA)  
_____ pacemaker/implantable cardiac 
_____ defibrillator/rhythm disturbance 
_____ heart valve disease  
_____ heart failure  
_____ heart transplantation  
_____ congenital heart disease  
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SYMPTOMS  
_____ You experience chest discomfort with exertion.  
_____ You experience unreasonable breathlessness.  
_____ You experience dizziness, fainting, or blackouts.  
_____ You take heart medications.  
OTHER HEALTH ISSUES  
_____ You have diabetes.  
_____ You have asthma or other lung disease.  
_____ You have burning or cramping sensation in your lower legs when walking. 
_____ You have musculoskeletal problems that limit your physical activity.  
_____ You have concerns about the safety of exercise.  
_____ You take prescription medication(s).  
_____ You are pregnant.  
 
If you marked any of these statements in this section, consult your physician or other 
appropriate health care provider before engaging in exercise. You may need to use a facility 
with a medically qualified staff. 
 
 
CARDIOVASCULAR RISK FACTORS  
 
_____ You are a man older than 45 years.  
_____ You are a woman older than 55 yrs, had a hysterectomy, or are postmenopausal.  
_____ You smoke, or quit smoking within the previous 6 months.  
_____ Your blood pressure is >140/90 mm Hg, or take medication.  
_____ Your blood cholesterol level is >200 mg/dL (borderline or high), or take meds. 
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_____ You have a close blood relative who had a heart attack or heart surgery before age 
 55 (father or brother) or age 65 (mother or sister).  
_____ You are physically inactive (i.e., you get <30 minutes of physical activity on at 
 least 3 days per week).  
_____ Your body mass index is 30 or higher.   
 
If you did not mark any of these or just one, you should be able to exercise safely without 
consulting an MD in a self-guided program or almost any facility that meets your exercise 
program needs. If you marked two or more of the statements in this section you should 
consult your physician or other appropriate health care provider before engaging in 
exercise. You might benefit from using a facility with a professionally qualified exercise staff 
to guide your exercise program. 
 
*2010 AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire  
2010 ACSM Risk Stratification 
 
Low Risk – individuals classified as Low Risk are those who do not have signs/symptoms 
of or have diagnosed cardiovascular, pulmonary, and/or metabolic disease, and have no more 
than one (i.e., ≤1) CVD risk factor.  The risk of an acute cardiovascular event in this 
population is low and a physical activity/exercise program may be pursued safely without the 
necessity for medical examination and clearance. 
 
Moderate Risk – individuals classified as Moderate Risk do not have signs/symptoms of 
or diagnosed cardiovascular, pulmonary, and/or metabolic disease, but have two or more 
(i.e., ≥2) risk CVD factors.  The risk of an acute cardiovascular event in this population is 
increased although in most cases individuals at moderate risk may safely engage in low to 
moderate intensity physical activities without the necessity for medical examination and 
clearance.  However it is advisable to have a medical examination and an exercise test before 
participation in vigorous intensity exercise (i.e., >60% VO2max). 
  
High risk – individuals classified as High Risk are those who have one or more 
signs/symptoms of, or have diagnosed cardiovascular, pulmonary, and/or metabolic disease.  
The risk of an acute cardiovascular event in this population is increased to the degree that a 
thorough medical examination should take place and clearance given before initiating 
physical activity or exercise at any intensity. 
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HEALTH HISTORY QUESTIONNAIRE 
 
The purpose of the following questionnaire is to assess your medical risk factors and 
determining your suitability to serve as a subject in a research study.  Should you be retained 
as a subject, all information from this form will be kept in strict confidence and will be made 
available only to the members of the research team.  This form will remain in your personal 
file in a locked file cabinet for the duration of the research study.  Should you not be retained 
as a subject, the form will be promptly destroyed.   
 
ID #_______________________      Date___________      
Height___________   Weight___________      BP______/_______ 
Physical Injuries and Limitations_____________________________________________ 
_______________________________________________________________________ 
Are you currently pregnant or think you may be pregnant? Y  N 
Have you ever had any of the following cardiovascular problems? (check all that apply) 
 
 Heart Attack/ Myocardial Infarction____  Heart Surgery   ____ 
 Chest Pain or Pressure  ____  Swollen Ankles  ____ 
 Arrhythmias/Palpatations  ____  Heart Murmur   ____ 
 Heart Valve Problems  ____  Dizziness   ____ 
 Shortness of Breath   ____  Congestive Heart Failure ____ 
 
Have you ever had any of the following? (check all that apply) 
 
Hepatitis/HIV    ____  
Rheumatic Fever   ____  High Blood Pressure  ____ 
Kidney/Liver Disease   ____  Obesity   ____ 
Diabetes (type)   ____  Asthma   ____ 
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Emphysema    ____  Thyroid Problems  ____ 
Stroke     ____ 
Total Cholesterol >220 mg/dL ____  HDL <35 mg/dL  ____ 
LDL Cholesterol >135 mg/dL ____  Triglycerides >150 mg/dL ____ 
 
Do any immediate blood relatives (biological parent & siblings only) have any of the above 
conditions?  If yes, list the condition, family relation, and the age at diagnosis. 
 
Is your Mother Living?  Y   N Age at death______  Cause________________ 
Is your Father Living?   Y   N  Age at death______  Cause________________ 
 
Are you currently taking any medications (prescription or over the counter), vitamins, or 
dietary supplements?    Y     N 
 
If yes, please list__________________________________________________________ 
 
_______________________________________________________________________  
 
If you are currently taking medications, vitamins, and/or supplements, are you aware of any 
that could change the rate or rhythm of your heart?     Y     N 
 
If yes, please list__________________________________________________________ 
 
________________________________________________________________________     
 
Do you now, or have you ever, used tobacco     Y     N      If yes, what type?__________ 
 
How Long?________   Amount______/day           Years since quitting?_______ 
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How often do you drink the following? 
 
 Caffeinated coffee, tea, or soda ______oz/day        Hard liquor______oz/wk 
 
 Wine______oz/wk              Beer______oz/wk 
 
Do you currently practice regular physical exercise?  Y  N 
 
 If yes, what type_________________________ 
 
 Frequency of exercise__________x/wk 
 
 Volume per week________hrs 
 
 Exercise Intensity________________________ 
 
What is your current level of emotional stress?  High       Moderate       Low 
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Thank you for your interest in this study.  Please adhere to the following requirements for 
participation in this study.  If you have questions or concerns, please contact Dr. Morris @ 
828-262-7120. 
 
Training Requirements 
 
1. Maintain consistent training durations and intensities for the duration of the study. 
 
2. Maintain a consistent training pattern for the duration of the study.  For instance, do not 
change the order of your hard and easy days. 
 
3. Avoid training on the days of your exercise tests and during the 24 hour period leading up 
to each test.  You are allowed no more than 30 minutes of exercise at ≤ 60% maximum heart 
rate. 
 
4. Keep a training log for the 24 hours leading up to each test. Bring this log with you when 
you come in for each test. 
 
 
Dietary Requirements 
 
1. If accepted into this study, you must maintain a diet record list of all foods consumed for 
24 hours prior to each exercise test.  Please bring this record with you when you come in for 
each exercise test. 
 
2. Do not use any vitamin or mineral supplements for the duration of the study.  This 
includes fatty acid supplements such as fish oil, flaxseed oil, etc.  Also avoid consumption of 
vitamin A,C,&E supplements for the duration of the study. 
 
3. Maintain a consistent diet for the duration of the study, especially during the final 3 days 
leading up to your exercise tests.  A list of foods to avoid is provided.  
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4. Do not use aspirin, ibuprofen, or compounds containing acetaminophen throughout the 
study. 
 
5. Please consume 1 liter of fluids the night before and 1 liter for fluids the morning of each 
exercise test. 
 
6. Please avoid high-fat foods 4 hours prior to each visit 
 
7. You will be given a small snack to be consumed 2 hours prior to arrival.  You will only be 
allowed to consume the small snack and water 2 hours prior to arrival.  Upon arrival, you 
will not be allowed to eat or drink anything other than the treatment fluid until after the 
exercise test. 
 
8. Avoid alcoholic beverages or caffeine 24 hours prior to each exercise test.  
 
9. Avoid chewing gum or mouthwash 48 hours prior to each exercise test. 
 
10. Avoid consumption of high nitrate containing foods 36 hours prior to each exercise. 
Examples: 
- processed/ cured meats (ex. hotdogs, lunch meats, bacon, corned beef, ham, smoked 
meats, and sausages),  
-leafy and root vegetables (ex radishes. carrots, any kind of potatoes, beets, turnip, 
parsnips, dill, broccoli, spinach, cauliflower, any cabbage, lettuce, mustard greens, 
celery, endive, fennel, kohlrabi, leek, parsley, cress, chervil, rocket (rucola), pumpkin, 
chicory),  
-vegetable juice,  
 
11. Please limit fruits to 2 servings and vegetables to 3 servings/day.  Please avoid fruits and 
vegetables 24 hours prior to exercise.  One serving of sliced fruits = ½ cup or one whole 
piece of fruit.  One serving of leafy vegetables = 2 cups; of non-leafy vegetables = 1 cup. 
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12. Avoid excessive consumption (more than 2 servings/day; 1 serving = 3 oz = deck of 
cards) of high fat foods throughout the study.  Avoid high fat foods 48 hours prior to exercise 
such as: 
-High fat meats such as, beef, pork, and fried meats 
-Oils, margarine, butter, gravies, high fat salad dressings 
-Meat or cream sauces 
-Eggs, regular cheese, whole milk 
 
13. Avoid foods containing garlic 48 hours prior to exercise. 
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24-h Food Record 
 
Name                                                                      Age _________                    
 
Height                             Weight                          Sex  __________                   
 
Home Phone                                   Work Phone ______________                               
 
Directions: FOLLOW FOOD LIST REQUIREMENTS.   
 
1. Please do not alter your dietary intake during the seven-day period leading up to each test.  
Some people tend to eat better or take in less food than normal while recording, and this 
decreases the usefulness of the final nutrient intake report.  Record everything you eat or 
drink, including water, juices, condiments, fats, spices, supplements, or medications. 
 
2.  Another major problem is inaccurate reporting of the size or weight of food portions 
eaten.  As much as possible, measure everything you eat with a cup, tablespoon, or teaspoon.  
Food portions can also be weighed (if you have a food scale), or the weight recorded in 
ounces as given in the food label.  When measurement of size or weight is not possible, 
record the portion size as small, medium, or large. 
 
3.  Do not rely on memory:  please take this food record with you and list foods immediately 
after they are eaten.  Please print all entries. 
 
4.  Please be as specific as possible when describing the food item eaten or fluid consumed:  
the way it was cooked or prepared, brand name, and if the food was fresh, frozen, smoked, 
stewed, fried, baked, broiled, raw, braised, or canned.   
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Date (Time 
food eaten) 
 
Describe Carefully the Food Item or Fluid 
Consumed and Method of Preparation 
Amount Eaten 
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24-h Physical Activity Log Record 
Name                                                                      Age ___________                     
Height                             Weight                          Sex ____________                        
Home Phone                                   Work Phone ________________                               
 
Directions: FOLLOW Physical Activity REQUIREMENTS.   
1. Please do not alter your physical activity during the seven-day period leading up to each 
test.  Some people tend to change their activity level while recording, and this decreases the 
usefulness of the final physical activity report.  Record every activity you complete included 
duration, intensity (or perceived intensity), and type of exercise. 
2.  Do not rely on memory: please take this activity record with you and list activity 
immediately after it is completed.  Please print all entries. 
3.  Please describe the physical activity completed in the last 24 hours. 
 
Date 
 
Describe Carefully the type 
of physical activity 
Intensity (or perceived 
intensity) 
Duration (time) 
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24-h Sleep Record 
Name                                                                      Age ________                    
Height                             Weight                          Sex _________                       
Home Phone                                   Work Phone ____________                               
 
Directions: Please come fully rested to each trial.  Sleep does affect performance, so please 
maintain a good quality sleep schedule throughout the study. 
1.Please describe the quality and quantity of sleep over the last 24 hours.  
 
Date 
 
Sleep Time 
(hours and minutes) 
Please describe quality of sleep (number of times 
wake up throughout the night, do you feel rested 
the next morning?) 
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Training History 
Name                                                                      Age __________                    
Height                             Weight                          Sex ___________                       
Home Phone                                   Work Phone _______________                                
 
Directions: Please answer the questions pertaining to the last eight weeks to current 
training status.  Please be as specific as possible. Ex. for interval training: work:rest, sets 
1.Please describe your training over the past eight weeks.  
 
Dates 
 
Type of 
exercise 
Frequency (how 
many days a week) 
Intensity (or 
perceived 
intensity) 
Duration (time of 
each activity) 
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2.Please describe your competition experiences of the past eight weeks.  
 
Dates 
 
Type of 
exercise 
Event Competition 
Level 
Results 
(time) 
Was this a typical 
performance for you 
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